Tag Archives: toxic

Pete Cohen films Pat and Steve Clarkson

Posted on by
Reply

——————————————————————
Pat Clarkson, and I come from Danville, California, which is near San Francisco, and I have multiple myeloma; which is not a common cancer
About 20,000 people in the United States have the disease, and about 10,000 die every year, and 10,000 get the disease
So it’s a relatively small number of folks,that have it
So it’s not well
It’s not as well researched as some of the other cancers, um, but we’re hoping that the, um, Burzynski Clinic can help me

There’s not much hope for me
I, I have probably, a, uh, prognosis of a couple, couple years
Maybe a year or two to live, um, without, um, without I, I, an alternative method of treatment, and that’s why
——————————————————————
If I could say this a little differently
The conventional medicine, or what we would call conventional medicine, which is, you know, chemotherapy, radiation, uh, surgery; which is not possible with, uh, multiple myeloma because there is no, no large tumor that can be surgically removed, uh, the doctors have told us basically there is no cure, and that, and I, I say doctors; this is our local oncologist, um, and the head of oncology at, um, University of California, San Francisco; which is a very well respected school, uh, hospital, that there is no, uh, no reasonable possibility of a cure
Um, by contrast, uh, Dr. Burzynski, we have found out, has, uh, cured several people with myeloma, and he’s cured many other people with different kinds of cancer
The problem is, uh, that the FDA in its wisdom, will not allow us to, uh, be treated with the, uh, antineoplastons that are the backbone of the Burzynski therapy
——————————————————————
Well they’ve told us that they don’t have evidence that it’s, um, that it’s an effective treatment
Uh, that, they don’t have evidence that it’s not, non-toxic; which in fact, uh, is incorrect because the FDA does have evidence that it’s non-toxic
——————————————————————
Through the Senator’s office at the, the FDA is saying that they, they don’t know for sure that it’s not toxic; that’s not true, uh, and they don’t know that it will cure the disease, and therefor they can’t approve it
We’re willing
Pat’s willing to take the odds of a treatment, that is not 100% guaranteed, and let’s face it, most of the treatments that are approved by the FDA, are toxic, and are not guaranteed
So we don’t really understand, uh, why they have an issue with it, except that, uh, there’s an awful lot of money involved
Um, one of the peculiarities of the FDA, we understand they’re, by law, required to get much of their funding from the very companies that they’re supposed to be supervising

As, as I understand, uh, the Constitution, there is no basis in the Constitution for the Federal Government to be telling, an American, who they can use for a doctor or what drugs that they can use for, uh, their, their illness
Yet, over the years this, uh, this power has grown and been accepted at the FDA, and now it’s a, uh, uh, it’s, it’s out of control
——————————————————————
We have asked the FDA what is different about my case
Why I don’t get an exemption
We don’t have a response yet to that, to that question
——————————————————————
While doctors are generally very bright; they have to be to get through medical school, but they don’t have any training in critical, critical thinking, and most of them that I run into are not particularly good critical thinkers
The world they live in is to memorize a set of symptoms, then to look up or remember what those symptoms suggest in terms of a disease, and then remember or look up what the treatment is

So, here we have, um, uh, Dr. Burzynski, who is also a Ph.D biochemist, which is a, a interesting and, and very useful, uh, combination, who discovered that, um, in people who have cancer, they generally don’t have, or they have very reduced levels of what he now calls, uh, antineoplastons, and neoplaston is simply the medical jargon for cancer; so it’s anti-cancer, in effect, um, he discover the people who, uh, don’t have cancer, do have, high levels of this, and determined from research that these are controlled by, um, by the genes, and it’s part of the body’s immune system, in effect
We all produce cancer cells everyday of our lives
Like we produce bac, or have bacteria in our gi, digestive tract, that is controlled, by certain genes
In this case, um, he discovered that by, uh, by injecting, uh, or infusing, uh, these, they’re called peptides, peptide, that the patient could be helped
How, how innocuous, or how anti-toxic, can you have
It’s a, it’s a substance th, the body itself produces, unless the genes have shut down
Which is the case in, uh, some, in most, or at least half I guess, of multiple myeloma cases
——————————————————————
My, my message would be that they don’t have the right to tell me to hold a, a life or a death, um, decision
They, they don’t have the right to tell me that, um, I can’t have treatment that I seek, or I will die
I don’t think they have that right to do that
——————————————————————
Treatment is available
Uh, it is our choice
We are free Americans
We’re well informed
Uh, well educated
It should be our choice, and the Federal government in any, in any form should not have the authority to interfere with that
——————————————————————
Uh, nothing’s guaranteed in this world, um, but we’ve got, um, we’ve got some confidence in this clinic and in this treatment
======================================
Pat & Steve Clarkson
January 27, 2012
Houston, Texas
6:25
2/3/2012
——————————————————————

======================================

Advertisement

Pete Cohen talks with Doug Olson

Posted on by
Reply

——————————————————————
My name is Doug Olson
I’m from Nebraska
Western Nebraska
And, uh, my mother has been diagnosed with pancreatic cancer
So, we, uh, middle of November, now this is first of, first of the year, eh, but in the middle of November her weight, she was losing weight, you know
She was suffering from indigestion and, and stomach pain, and so we started to have her checked, uh, for problems with her stomach for ulcers and that kind of thing, and all that proved negative, and they put her on an ulcer medicine anyway, thinking that maybe that would solve the inflammation in her stomach, and, uh, then we decided that we (?) better see another physician, and so we did that, and they then ultra sounded and then CAT scanned and found that she had tumors in her pancreas and in her liver
Uh, many years ago, back in, in the late 70’s, my parents had been involved with, with the cancer, uh, subject in regards to my father’s sister, and then his cousin
He started researching cancer and cancer treatments when his sister passed away, and then, uh, they got in contact with a doctor in Orden, Nebraska, that treated cancer patients with Laetrile, and he also did other, not so ordinary things
He did duculation therapy
Uh, a number of things that were really treatments for the disease rather than just treatments for the symptoms, and, uh, during that time, dad testified at the state legislature; they were trying to work against Dr. Miller’s license
This was the Dr. Miller in Orden, and, uh, so dad testified on, on his behalf
Uh, dad’s cousin was, uh, a patient of his, and she had a brain tumor the size of a lemon, and Dr. Miller put her on, uh, Laetrile treatments on a, on a special diet and some things, uh
——————————————————————
And this was what, in the 70’s ?
——————————————————————
This was back in the, probably the late 70’s, and, so, when they
Well they cured her
She had been sent home from the Mayo Clinic
Given 3 to 6 months to live, and, uh, they had, uh, burned with radiation and cobalt I believe is what they were treating her with at that time
Uh, they burned the, uh, nerves in her eyes so that her eyes crossed
Uh, they sent her home to die
They, uh
She was in a wheelchair
She was a young woman and she had a young child
Wasn’t able to hold that child, and so when my dad saw her, met her, she was in that condition
She was it, in the last 6 months of her life
Gave her a book about, uh, the subject, and told her about Dr. Miller, and her family
She then went to Dr. Miller to see if there was any help for her, and he, and he immediately put her on Laetrile treatment then and, and, uh, the interesting thing about it, looking at his doctor’s protocol; because I’ve come across his protocol, uh, Dr. Miller was also giving his patients antineoplastons, and
——————————————————————
Yeah, because we’ve got this thing here that you gave me
——————————————————————
Mhmm
——————————————————————
Just explain to me what this is
——————————————————————
This was his physician’s protocol, to list, uh, the different medicines a person should, should be on
——————————————————————
If they had cancer
——————————————————————
Uh, if they had cancer, and so, uh, this was given to another friend of ours, a friend of the family, uh, the folks that rented one of our properties, uh, the woman got a, a tumor as well, and this was given to her as part of the regimen she should follow, and she was given Laetrile injections, and then as soon as the injections, uh, were over they went then to pills as the size of the dosage went down, and when you got to pills you got to go home
So, uh, I remember speaking to her at the time
I had a
I was in high school, and I had a summer job with her husband, who was the county engineer
So, uh, we saw them all the time, and she told us, uh, the circumstances when, when she was allowed to come home
She was feeling strong
She said: “I haven’t felt better”
As a part of the diet and the things that, that they had her doing
She said she felt better than she had in many years
So she and her daughter, started a business in town in order to pay for the treatments, and, uh, she recovered
The tumor continued to shrink and shrink until it was nothing
Uh, what had been listed as inoperable, uh, after it shrunk halfway they decided, well maybe we can operate on you
Uh, we think it’s operable now
She said: “Why would I let you operate when what I’m doing is working” ?
But, uh, she is alive yet today and in her mid-80’s and, uh, so, uh, when it came to my mother’s illness, we contacted her, and asked her how she’s doing, and she’s sent this protocol she’s been keeping all these years
Uh, as a result of my parents knowing Dr. Miller back when he was alive
He is, he has passed away, uh, 7 maybe years ago, and, uh, many years ago when they were taking chelation therapy from him, he had given my mother, uh, a flyer on Dr. Burzynski, and, uh, said if anything ever happens to you after I’m gone, this is the man to contact, and so we’ve had that flyer in a file for many years at my parents house, and so when mom got sick she immediately began digging that out and found
——————————————————————
So your mom immediately started thinking, well I need to find that leaflet
That’s what we were told to do
——————————————————————
Yes
——————————————————————
And did, and did she go and speak to an oncologist ?
Did she say that she wanted to come here, or ?
——————————————————————
We had a local physician, who was not an oncologist, that had, that was the 2nd physician we, we consulted, that did the ultrasound and the CAT scan for her and, and they knew that she had tumors, and no we did not go to an on, oncologist from there
——————————————————————
Why ?
——————————————————————
because we knew that we did not want to take their treatments, uh, so we immediately contacted the clinic here in, in Houston, Texas, and, uh, we had to wait on, uh, certain things to be completed
CAT scans
Different things had to be done, and, and information had to be sent down here and examined, and then, uh, after a period of maybe 2 weeks, hassling with information, we were told that, yes, uh, we, they would accept her as a patient, and we were getting in towards the holidays at that time
Would we like to wait until the holidays were over, because Christmas
You know, there would be 5 days off for Christmas, uh, over a weekend and 5 days off for New Years over a weekend, and we would be down here in Houston over those times, but we elected to come anyway because we could get the treatment started right away
——————————————————————
Mhmm
——————————————————————
rather than to wait another month before starting treatments, and, uh, so they, uh, immediately put, put her on antineoplastons and, uh, they sent away the tissue samples to Arizona to have a CARIS test done, and determine what medications would be
——————————————————————
So did you have those results come back ?
——————————————————————
Yes, those results came back quicker than what we expected
——————————————————————
And wh, what did they show ?
——————————————————————
Well they, they show a, a list of treatments that are effective, and against it, and then a list of treatments actually that encourage it’s growth
——————————————————————
Yeah
——————————————————————
So you end up with a list of, uh, approximately 7 on each side
7 good
7 bad
——————————————————————
And these are all different cancer drugs
So what they’re looking at is all
——————————————————————
Yes
——————————————————————
is all the different cancer drugs, and which ones
——————————————————————
And whether we’ve got a, a thousand or 2 thousand different drugs that person might try, and, uh, so
——————————————————————
So the (?) for how to, to try a few of these chemotherapies, but in very small doses
Is that right ?
——————————————————————
There’s 2, 2 chemotherapies
One is an, is an oral chemotherapy that is, uh, quite mild in its side effects, and then, uh, there’s another much stronger one that was, uh, also one of th, the top 2, and, uh, the side effects for it are more varied and more violent, uh, if you will, and, uh, my mother’s had one treatment of that so far, and the treat, the side effects
She did, is suffering from side effects from that particular
——————————————————————
Yeah
——————————————————————
It’s Oxaliplatin, and, uh, some people have very violent side effects but she’s thankfully not had any violent side effects
——————————————————————
So why didn’t you go down the conventional road of having high-dose chemotherapy ?
——————————————————————
Well, when you research the, uh, success rate, with pancreatic cancer, going the normal way, uh, or the normal, uh, road, the success rate is very, very small, and so you’re just guaranteeing, in my opinion, if, if the success rate is 5% or under, uh, you’re introducing yourself to a, a road to death, that’s very unpleasant
——————————————————————
Yeah
——————————————————————
You know, you just want to go home and make yourself very comfortable on painkillers and, and enjoy the rest of your life, uh, if that’s the, if that’s the road you’re planning to take
——————————————————————
Yeah
——————————————————————
Uh, that was our opinion, and so
——————————————————————
What do you think about all the resistance then of, of Dr. Burzynski and all of the kind of, uh, ?
——————————————————————
We have
——————————————————————
(?) people just calling him a
What’s the word ?
——————————————————————
Charlatan
——————————————————————
Charlatan
Yeah
Fraud
——————————————————————
Yes, we, uh, we have seen course, of course these things through our, our life
Dr. Miller
The whole Laetrile treatment thing was something that was, uh, thrown out
You know, it’s pretty well suppressed now
You can go to Mexico and get those treatments
——————————————————————
Why do you think they were, pushed aside ?
This Laetrile
——————————————————————
It’s
——————————————————————
What is Laetrile ?
——————————————————————
Well Laetrile is a naturally occurring, uh, substance that you find in some of our foods
It’s, they call it B17 although, vitamin B17, although there’s some discussion as to whether it’s really a vitamin
Another name for it is Amygdalin
——————————————————————
Amygdalin
Yeah
——————————————————————
Uh, it’s found in peach pits and apricot pits in high levels but there’s a number of other foods that you find it in
Uh, it, it,
I’m not sure, whether this is 100% accurate, but my understanding of it is it’s associated with, with cyanide, and it would be, uh, like an encapsulated cyanide, that as it travels through your body, the cyanide portion, um, does not become available to your body until it becomes in, uh, associated with a cancer cell
——————————————————————
Yeah
——————————————————————
and the cancer cells attack the outer shell of that molecule, and the cyanide becomes, uh, uh, available then, and it kills the cancer cell that’s right there
So it was apparently a very nontoxic substance
Uh, you have regulated dosages
I mean, it seems to me interesting, uh, when a doctor prescribes a dose of chemotherapy, uh, there’s nothing that I can think of much more toxic than a, than a chemotherapy drug, and certainly they’ll kill you if they don’t, uh, give you the right dosage, but it was not seemed, deemed accessible that a byproduct of food; which a doctor could regulate the dosage of as well, could be used as a transfer, cancer treatment
——————————————————————
Yeah
——————————————————————
Uh, and we’ve seen things in the past, as well
When I was a, a very young child, I had a great aunt, that, uh, I was not even aware; at the time I was very young, she was traveling to Texas and getting treatments
Uh, one of them was called the Hoxsey treatment and, uh, she was living a very comfortable life on treatments that she got there
There were 2 treatments in Texas at that time, that, uh, were available
The FDA would come in and raid the clinics, and make just life miserable for them
They got one of them closed down, and that was the one that my great aunt was on, and that treatment was, was pills that she could take, uh, and live quite comfortably, in Nebraska
Once they closed that clinic down, then she had to go down, uh, to the other clinic in Texas, which was a supplement that was a liquid that tasted bad, and she had to make frequent trips, at that point, but still, as long as she could get that treatment she was comfortable and, and lived a normal life
A productive life
Uh, we knew her as our great aunt and, and didn’t even know her, uh, uh, that there was a health problem and, uh, but then the FDA got that clinic closed down
So, as soon as she lost access to those, her treatments, then her cancer which, uh, was no longer able to be controlled, came back strong and, and she died
So, uh, the family had been, had access to this knowledge and this, the FDA’s games with cancer treatments for many years
Um, I’m also married to, a, a gal whose father did blood research as a, he was a Ph.D and worked in university hospitals, in blood research all of his life
He, he discovered a blood protein that was associated with cancer
Uh, it was actually associated more with good health, maybe than you could say with cancer, but he discovered a, a blood coagulation protein, uh, or associated with blood coagulation that would, that could be used as a flag or a test, to see whether a person was healthy or not
Uh, as they applied it to patients in these hospitals, during their research trials, they found that this protein was an indicator whether a person had cancer or thrombosis
Uh, 2 of the very largest killers, and this protein, if present in high enough amounts in our blood, uh, was an indicator that you were healthy, and as the protein’s amount, uh, declined, then it was an indicator that something was wrong, and below a certain amount you knew something was wrong
You better be taking further testing
——————————————————————
Mhmm
——————————————————————
to find out what your problem was
Uh, that has run into resistance
Uh, that (?) has not been approved by the FDA, and, uh, th, our family’s experiences with cancer treatments, cancer drugs, as they’re affected by the FDA, we have determined by our opinion that, uh, it’s, un, unless there’s something that’s going to generate a, a lot of capital, and then a lot of tax money for the Federal Government, the FDA’s not very interested in it
——————————————————————
Yeah
——————————————————————
Uh, so, cynical attitude, but evidence bears it out
——————————————————————
Yeah
——————————————————————
and so we remain cynical until so, until something proves
——————————————————————
Yeah, absolutely
So this is this doctor in, uh, in the 70’s
This is information that he provided
——————————————————————
Yes
——————————————————————
and you can see here that he is obviously, antineoplastic enzymes
See, here obviously
Do you think he meant Dr. Burzynski ?
He just knew of him ?
You have no idea ?
——————————————————————
I have no idea
——————————————————————
He was obviously a fan, if he was someone that eventually said
He said it to you
Did you say he said it to your mum or to your dad?
——————————————————————
To my mom
Probably to mom and dad
——————————————————————
Yeah
——————————————————————
Uh, my mom was the record keeper, and so, she kept the flyer
——————————————————————
Yeah
——————————————————————
but they both took, uh, the, uh, the therapy from, uh, well, the blood therapy
I mentioned it earlier
Suddenly the name’s gone away
——————————————————————
Yeah
——————————————————————
but, uh
——————————————————————
That’s ok
——————————————————————
So
——————————————————————
So what about, um
You know, one of the barriers that we had is, when we spoke to oncologists, they just said, no, you mustn’t come to see this guy
His work isn’t peer-reviewed
He’s a charlatan
Why, why do you think they would say that ?
What
I mean I’m surprised, that these oncologists don’t actually come here, to actually see what, what’s going on
So your opinion about that ?
——————————————————————
My opinion is, that physicians are, very much, tied up, with large pharmaceutical corporations
Uh, I spoke with my father-in-law
My father-in-law had to have research done in, in his Ph.D work, and he had to get cooperation from hospitals, from doctors, and, uh, all of these organizations in order to have the research done that he needed done, ’cause past his lab, when he wants to introduce research, onto a patients, uh, live blood, and he needs to collect specimens from patients, then a whole ‘nother group of, uh, set of authorizations have to be signed and, and he being a Ph.D working with the medical profession all his life, he knew how tied up the medical profession is, by, generally by M.D.’s, that control the money flow, uh, in the medical profession
Ph.D’s do the research, but they have to apply for grants, and typically the grants are controlled by M.D.’s, and so if an M.D. Decides that your, your particular research is either applicable to, uh, something they think will make a lot of money, or it’s the, the quote, uh, popular, popular item of the day
——————————————————————
Yeah
——————————————————————
Politically correct, you name it, then you’re going to get funded
Otherwise, uh, my father-in-law noticed at different times, his research had to be funded out of his own pocket, and at other times, it looked like, it was something that doctors would like, and so they would, he would get funding, but I think that, ah, as he commented, any doctor, coming out of med school, has been contacted by a pharmaceutical company, and has probably signed a contract, that when that pharmaceutical company wants to test a drug, or test an item, that that medical, uh, doctor, will be accessible to them, to test their products
So, with the number of pharmaceutical companies that you have, and all of them recruiting M.D.’s as they come out of med school, and saying, you know, would you be part of our group, you end up under contract with the large pharmaceutical companies
——————————————————————
Mhmm
——————————————————————
and if, if 90% of the doctors are under contract with pharmaceutical companies, to, uh, to cooperate with their drug testing, then large Pharma, has control of virtually all doctors, and so, uh, uh, if you have large Pharma saying, we don’t want to see a cancer cure, that we’re not in control of, we don’t want to see something that makes curing disease cheap, and easy, and food related, then you’re not gonna
They’re going to put the word out to all their doctors: Don’t have any wo, don’t have anything to do with this
Uh, they can come up with, some written material for their, their doctors to read
They send them the evidence
——————————————————————
Mmm
——————————————————————
It may be accurate
It may not be very accurate, and, uh, but it’s just a smear campaign to destroy reputations so that they don’t get hurt financially
——————————————————————
Mhmm
——————————————————————
and, uh, so, uh, that’s the reason I believe
You know, most of these doctors, they don’t have the time, or the expertise to do the research themselves
They can’t read everything, and so when someone they trust, or someone that they’re financially, uh, obligated to, comes down and says: Here’s the stand that we want you to take, and it’s against this particular treatment, or against this doctor, they do what they’re told
——————————————————————
Yeah
——————————————————————
They do what they know best
Uh, my father-in-law, for instance, was, uh, also involved as a professor in these med centers
He taught nutrition, and he said it’s always a, been amazing to me that you can get through med school, and never take a class on, on nutrition
So you can become an M.D., and not understand the value, of nutrition, to a person’s health
That’s a problem
Uh, he recognized it as a problem
I recognize it as a problem because I particularly believe that most of our ill health is because how we treat our bodies
What we eat
——————————————————————
Mhmm
——————————————————————
Whether we exercise or don’t
Whether we provide our body with a way to flush the poisons or not
Uh, healthy living, and if you don’t teach our medical profession, healthy living, how can they teach their patients
——————————————————————
Mhmm
——————————————————————
So this, this whole system is, is just flawed in some ways, and weak in other ways, and, uh, controlled, for the purposes of commerce, instead of the public
——————————————————————
Yeah
So you, you think it’s a good idea treating people as an individual and finding out what they need as opposed to like carpet bombing them ?
——————————————————————
Absolutely
When we understood the, the individualized approach, here at the Burzynski Clinic, that they would take where they would test the cancer cells, uh, against all of these treatments and all of these chemotherapy treatments and, and anything else that might be out there that would, would treat cancer, and come back with a, a individualized care approach to the individualized cells of cancer that my mother has, that’s when we knew that we had to come here
We wondered, and I’ve told my friends, and everybody wonders, that oughta be the standard approach everywhere
Why wouldn’t you test, every cancer, and see what it is that’s gonna treat it best ?
You, you tell me
======================================
Doug Olson chats with Pete Cohen
January 2011
25:00
11/9/2012
——————————————————————

======================================

Pete Cohen chats with Dr. Stanislaw Burzynski

Posted on by
Reply

======================================
Pete talks with Dr. Stanislaw Burzynski
——————————————————————
December 2011 (1:02:30)
======================================
How did you kind of get into this, into this field in the 1st place ?

Uh well, it was a coincidence, ’cause obviously I made discovery of new chemicals, peptides which is in blood, and I noticed that they were deficient in patients with cancer, and there was a curiosity, why there was such deficiency, and I was interested what these peptides that I discovered, are doing in the body
So the connection with cancer was quite obvious
He, healthy people have abundance of these chemicals in blood
Cancer patients have varied to none
So could be that cancer is another deficiency disease
So

So when you found this out

Yes. Mhmm ?

how did you feel ?
I mean, did you not just want to shout from the rooftops, and could you believe that you’d actually discovered something ?

Not yet
Of course I was skeptical, and I found something that was interesting, but obviously, it was just the very beginning and when I shared this news uh with some other guys, who are obviously much older than me, who, other guys who were professors, who ever, so (laugh) they began to laugh so much they almost died from laughing
Ok ?
That (laughing)
Wow, this guy would like to kill cancer
Forget it
Ok ?

That’s just not going to happen

What are you doing ?
Yes sir (laugh)

Well how did that affect you ?

Well it didn’t affect me too much because I knew that uh the science uh requires uh some successes and uh setbacks and I felt, well I still would like to know, what these peptides can do, and I would like to know what they can do, not only regarding cancer but in various aspects of body function
For instance, the activity of the heart, the activity of the uh uh G.I. tract
Whatever
Ok
I needed to expand this knowledge
Suddenly I found some like 119 new peptide fractions
Nobody ever heard of them
So I wanted to know
What do they do ?
And when I was in Poland I couldn’t have really do any further testing, because I didn’t have such possibility to require different group of people who would do the testing, and simply by working in the biochemistry laboratory I did not have such capacity, and obviously the budget for doing uh research was extremely small
Besides, I was continuously harassed by the communists and they were sending me to, eh, the military, so I couldn’t do much
I still did whatever I could
Then I came to U.S.

Oh so you came to U.S.
What, what year was that ?

It was 1970

I heard you came with not very much money in your pocket

Uh well it was better than where I came first to the U.K., because when I came first to U.K., I came practically with nothing, and uh, when I went to British uh Medical Student Association, they were going to give me 7 pounds for one month stay in U.K. (laughing)
You were supposed to get this money in Poland

Yeah

(laughing) Sorry about that
So ultimately they decided to give me 7 pounds, and obviously at that time it was a lot of money, so with 7 pounds I was able to survive a month
(laughing) Good luck (laughing)
But in U.S., I was allowed by the communist government to $15, which again, was equivalent probably to 7 pounds, whatever (laughing)

So you came here with $15

I smuggled another 10

Yeah

So the proper balance was like

So what
So what did you do when you got here ?

Well, ehhh, when I arrived I was uh, uh, uh, trying to get ahold of my relatives
My uncle that lived in Bronx

Yeah

And uh I officially came to visit him and uh I was expecting him to see me at the airport, and surely enough he came to the airport but uh at the time he was an elderly man
He was close to 80, and eh, he probably went to a different part of Kennedy airport, so he couldn’t find me
So I was stuck in the airport
This was Holiday
This was 4th of uh September, which was a Labor Day, and so I couldn’t get uh uh to his apartment
So finally I spent most of this money for the cab, the taxi rides to his apartment
Some, like $13 worth

You had $2 left

Ye, Yeah

Plus the $10

Sure
Well, so then I stay uh I, I was obviously in the family’s, I couldn’t

Yeah

I, I don’t need to worry about it
So obviously I had a food and lodging, and uh, still I was trying to get hold of some of the people whom I knew were doing the research in the area, whi, which I was interested

Mhmm

which was peptide research, and uh trying to see if I can advance my research
And then I thought, well, if I go back to Poland, I didn’t expect to stay
And in the meantime uh my job at the university in Poland was terminated, and I wondered they needed my position for the woman who was the wife of the 3rd Secretary of the communist party
Finally when I was terminated from my job, uh, there was no need for me to go back, because I would not be able to find job anywhere in Poland, because obviously everything was controlled by communist
So that I decided to stay and to look for the possible, possibility for me to find a job in the U.S.

And wha, what job did you find ?

Um

So you were in New York ?

Yes, I was very active, of course since I was involved in the research
I knew the key people who were involved in peptide research
There were not many of them, but at least there was one good team in New York and Columbia
Um, there was another one at, uh, Cleveland Clinic, and there was another one in Houston, and so, uh, I check with all of them and, uh, the place in New York was unavailable because they hired, um, somebody, um, about a week before I came
Uh but uh, uh, I was invited to the interview to Houston
I was surprised but uh, prepared for my trip and I arrived to Houston and had interview with a professor at Baylor College of Medicine and he gave me the employment, and so it was relatively simple

And then what were you doing on like a day-to-day basis ?

Uh, well, uh, when I arrived to Houston I uh, obviously received a job
I received the job as “Research Associate,” and um, obviously this was associated with a reasonable salary, but the salary was paid once a month, so I had to think, what do I do for the 1st half of the month, because I came in the middle of the month, and didn’t have any money (laughing: both), but some good people loaned me some money so I, I have enough money to rent the apartment, and finally after I got my pay, I was able to do quite well, and I was able to advance, uh, in peptide research

So were you able to do your own research or

Absolutely. Absolutely

that they wanted you to do ?

Absolutely, and uh, I was quite lucky to join the team of the famous professor
Professor George H
er, uh, who was initially professor of Sorbonne in Paris
Then in World War II he emigrated to U.K. and he was professor at Oxford, and so finally he came to U.S., and, uh, he put together the peptide research team
He needed people who know how to do analysis of peptides, so that’s why he hired me
And uh I uh told him that I have my own project, which is peptides, and if you wouldn’t mind that I do some research of mind, and he agreed
So basically this was gentleman agreement that I will spend 50% of my time working for him, and spend 50% time, working in my area
Uh, the equipment and the instruments were the same, so it wasn’t too difficult

And then you, and then when you had something to show then, when. when you had even more of something to show them, how was that received, because you see, I’ve really got something here ?

Ah

I think I’ve got something here

Absolutely, it was received with great curiosity, and, um, and obviously he needed people who could use, the cutting edge, uh, methods for peptide analysis, and that’s what I knew about, but I couldn’t use this for him because I didn’t have funds to do it, but I knew exactly what needs to be done, and on the other hand, uh, this was great surrounding because just across the corridor, another team receive a Nobel Prize for working on peptides
The only problem is, uh, one of these researchers uh was of Polish origin who received Nobel Prize for peptides (laughing)

Yeah

began, uh, fighting with the other one and finally his job was terminated because he punched (laughing)

Punched him ?

the other guy in the nose (laughing)

Yeah
Huh

So, but the good thing about it is that ultimately I inherited uh, their equipment

Yeah

for peptide research, so

Wow. So that must have been like a, like, a, a child in a sweet shop

Absolutely, so was a great coincidence so

So then you were really able to, to, to, to look at it in more detail, and ?

Absolutely, so then of course I was really out of work uh, and the team of Dr. Unger, and also, uh, I was spending a lot of time, uh, progressing in my research, which was very important uh, of course it means long hours uh, ’cause of, uh, 8 hours I would spending working for Dr. Unger and probably not 8 hours until midnight working on my uh, project, but uh, I enjoy it
In the meantime I need to prepare for exams because I wanted to have a license
So I was lucky because uh, within 3 months I was able to pass exams to uh, to naturalize my diploma, and then uh, just, uh, the day, on the eve of my birthday, on January 22nd, President Nixon had a speech in which he promised American people that by 200th anniversary of America, they would have a cancer cure, and no limits would be set on the funding
So then I thought, well, if that’s the case, perhaps I should apply for the grant also, and I did
It was crazy idea because I could barely understand when the people were talking to me (laughing: both)
Well I decided to put together grant application, in to the National Cancer Institute, and include the project on the peptides which I discovered, and I was surprised when this was approved
So then in uh 1971 I get approved as Principle Investigator, to do the project, which included eh, the top people from M.D. Anderson Cancer Center, and from Baylor College of Medicine, um, and I was supervising this
I was at that time 28 years old, but I was supervising the guys who were famous, and who were some like 60 years old (laughing)

Wow

and so the money was coming to me from the National Cancer Institute, and I was uh daily uh, running the project, sharing, obviously with the guys from M.D. Anderson, so, and going ahead with the research, so
and of course at that time I was disappointed to have to (work ?) with M.D. Anderson and Baylor, and then I could move independently what I was doing

So at what point were you actually, able to start testing on people

Mmm
It took a long time because

I mean you couldn’t wait, right ?

Yeah it took a long time because obviously um, initially you have to go through a lot of pre-clinical testing
The 1st time it was uh, around the beginning of ’77, yeah
So then we began phase I clinical trials, and this phase I clinical trials were approved by one of the very good hospitals in Houston, which is part of the hospital chain American Medical International, and they interviewed my project and their Institutional Review Board approved it for clinical trials
Well then I did my 1st clinical trials, phase I clinical trial, with a medication that I am not using at this moment because we made further progress of course, at a hospital, and this hospital at that time was called Twelve Oaks Hospital
At this time it’s called River Oak Hospital

Yep

Yes

And then, at what, at what, was there a time where you realized: This is actually working ?

Well, now this was in 1977, and (laughing) surprisingly, uh, uh, perhaps one of the 1st successful case where you can really, document a clear-cut improvement by doing the scan before and after
It shows tremendous decrease of uh, uh, tumors which corresponded to colon cancer which spread to the liver
(This guy was ?)
(laughing)

(?)

(laughing)
And uh, his case was so interesting, that when I sent it for press, the editors decided to put us on the cover, of the journal, the scan

Yeah

They decided to put on the cover of Science, showing the tumor before, and, after the treatment
Eh, so this was uh , obviously

And then what happened ?
Didn’t that m kinda, didn’t word spread like wildfire and people, more and more people want to come and see you ?

Ah, Absolutely, well the 1st excitement occurred, basically what the President Nixon promised ok

That he would deliver

Yeah

cancer cure uh, by ’70, uh 6, 1976, and we did, ok, and we did deliver cancer cure

Yeah

by 1976, 1977 ok, and um, the um, main uh event was the presentation of uh our theory on our research, on perhaps one of the largest uh scientific (congress ? conference ?) in America, involved 19,000 uh, researchers attended
Eh this was annual meeting of the Federation of the Societies of Experimental Medicine and Biology
It happened that at that time it was in Anaheim, California
Uh, I sent uh, uh, the abstract of my presentation, and I was simply, patiently waiting until this would be shown, which was in ’76
In June ’76 right before 4th of July, and uh, I was surprised when they notified me that um, my abstract was selected out of one of few, which was in great interest of the news media, like Associated Press, for instance, and then when I did my presentation, then Associated Press decided to make a release of this, and then you can read about it in newspapers all over the world
In uh, (laughing) distant places like Buenos Aries, receiving CBS newspaper clips from all corners of the world

And what was that like for you ?
I mean, how did that feel, just to see that your name was, all over the world ?

This was the 2nd time, what (?) this happened to me, because 1st time it made such news, by working on brain peptides with Professor Unger; this was around ’72, and suddenly, this wasn’t so much of my

Yeah, but still it was your (interest ?)

involvement, but I was working together with Professor Unger, and we made a great news, by discovery of, certain peptide in the brain, and then it spread all over the world, and then again, uh, uh, CBS

What was that like ?
I mean, how did you feel when you saw ?

Well, uh, it was surprising because uh suddenly we got uh news people coming, and the TVs from various countries, especially from Europe, for instance, from variety of corners, like from Europe, from New Zealand, from Brazil
You name it ok ?
Eh, so there was a great excitement about it, but 1st time that this excitement happened was, is around ’72, uh, really, eh, is typically what happened after such excitement, is the ? iation ?)
ok

Yeah (laugh)

Well, uh, (laughing) the uh, establishment is and this um will attack you and will try to destroy you

Did you know that was going to happen before ?

I knew it would because in Poland, uh, my father’s, uh, gave me the book of um MIT Professor, uh, Thomas Kuhn
(here’s a guy ? try to translate to (?)
(laughing)

(?) yeah
Yeah, probably

(laughing) sure
and then uh, this was uh, the book which was titled eh, Structures of Scientific Revolutions
It happens that this book was translated to Polish language as couple of years after it was printed, in U.S.; which was around uh, I think 19 uh, 64 probably, ok
So then I read the book, and the book shows uh, how, eh, the paradigm shift occurs, ok, and the, it never fails
It always goes through the same stages
1st it’s short period of excitement, and the a long time of harassment and persecution, and then finally the brief period when uh, uh, if you survive, then uh, the other people say
well it’s obvious
We always knew (laughing) that this

Yeah

was going to happen, ok ?
So I knew what was going to happen, uh, but uh, it was hard for me to believe it uh that, uh, in the 20th century, 21st century it could happen, ok, but then uh, when uh, I began going through this, it was like going to some uh, unpleasant disease
You read about it in the books and

Yeah (?)

then uh, you finding one symptom after another, and it affects you

Yeah

and you know that it could be deadly,
(?) survive

Well you could have ended up in prison, right ?

Yeah

(?)

You may die before uh, you be able to do anything

Mhmm

So the advice of the author of the book, was that you have to start early to make some medical discovery, because you probably have years of harassment in front of you, and probably the best chance that uh, you get accepted if you live longer than your opponent, because some guys will never accept you (laughing)

Yeah

until they die
So that’s what happened
Well then, of course, I witnessed what happened with Professor Unger
Yeah, he made the great news, and obviously I contributed to what he had, but he was uh, my boss, and then obviously I did not much, suffer much from retaliation, but he did, ok
So there was retaliation, and uh, they accused him of everything possible, uh, finally causing for him to move from Houston to Memphis, Tennessee, eh, zzz, about year later he died
So unfortunately his research was never brought to the time when it was accepted, ok
It was great research, ok, and if had really to more resource and time I can bring this to be accepted, because this isn’t a completely different field
This is brain function, memory, and peptides working in the brain
But at that time unfortunately the project was killed, which is great loss for humanity, eh, ’cause the discoverer passed away, and the product was gone together with him
It can be still resurrected, and I think it will be
Eh, so then, for me, eh, it meant only advancement, unfortunately, because, uh, when uh, uh, he was stripped from the funds, I received funding from the National Cancer agency funding from the university, and I was able to support him, because he was stripped of his grants and funds
So he was able to move forward with his research, but finally when he moved, I inherited very large laboratories
My laboratory was located in 3 buildings
So the lab space and uh, uh, some prime location, in the medical school
So then I did very well, then, of course, the publicity occurred, and this publicity was centered around me, not around both of us

Yeah

at that time, in ’76, and then again there was about 1/2 a year when there was a great enthusiasm, uh, good wishes, whatever, and after that, a retaliation occurred, ok
So then obviously

Mhmm
And what was, what, what was at the heart of the retaliation ?

Uh, well,

The fact that their people didn’t want this to come to the fore ?

Initially there was some overtures to take away the discovery from me, and uh, for instance, uh, uh, uh, Baylor College congratulated me
I received diploma, so suddenly became superstar, ok (laughing)

Yeah

and then, of course, uh, the wise people, the business people from the university said: “Look, probably we should talk now about patents, we should talk about pharmaceutical companies, we should try to, somehow, put this to motion,” ok, and that’s what we did
So then uh, we talked to some of the best lawyers in the country
Of course, uh, the university uh, are in control of this
There were visits of uh, pharmaceutical companies
I remember one of them came from the research center in U.K., from High uh, Wycombe , and this was so (encouraging that ?) was very interested, what we do
But then uh, the intention was just to take uh, my, uh, in, invention away from me, and obviously

Mhmm

I would have very little to, to, do to promote this, to develop this any further
So I thought about it and I felt that I’m not going to do it
There then uh, I was offered to join the mainstream cancer research at Baylor cancer medicine, and obviously uh, I would receive much better title, of professor

Yeah

and obviously there would be much better equipped laboratory, but again eh, they wanted me to, completely quit private practice of medicine, ’cause at the same time I was practicing medicine, which many researchers were doing
I was working at Baylor College and then I was practicing medicine uh, outside Baylor College, in the group of the other doctors
So in this way I had some independence, because obviously, I could always practice medicine (laughing)

And did you always want to keep your independence,

Yes

and did you know that was always a good thing ?

That’s right, that’s right
Because I, I did not want to be uh, at the mercy of the university or the government
Uh, but I still wanted to stay in academic surrounding, because obviously I came from a family which has great tradition of academic careers
So that’s something which obviously my father was always telling me that I should be really staying in the university, ok
Eh, uh, uh, but finally I decided that I was not going to accept this offer because uh, why should I resign from my private practice

Mmm

It didn’t hurt my research in any way
So I decided to continue, and uh, then that’s when the retaliation occurred, and uh, I was (crazy ?), harassed, and attacked, and finally

And how were you harassed ?
I mean, letters or (peop ?)

Mmm, well, as I could do the research for such a long time, because really, this was some like 7 years at the university, because uh, very few people in the university knew what I was doing, because I was only responding to the National Cancer Institute, and uh, I was not part of the mainstream cancer research center
What happened is that uh, (laugh) I was employed by the Department of Anesthesiology, which obviously, on the surface has nothing to do with cancer, but, who cares ?
I was receiving grants from the National Cancer Institute, and so Anethesiology was a very wealthy department, and they had a lot of space, but they were doing very little research
So they wanted to do some type of research, and uh, the chairman of the department was supportive of my doing cancer research
So basically I conducted uh, Anethesiology
laboratory into cancer, into cancer research laboratory, and very few people knew about it
They learn about it
when uh, the Associated Press (laughing) broke the news
So then uh, the retaliation happened

Mhmm

and then they wanted me to join the mainstream, but obviously I was enjoying very much (laughing) working, in peace and tranquility, and responding only to the National Cancer Institute
So then uh, what happened at that time was that uh, obviously Dr. Unger, moved to another university, and um, uh, the chairman of the department uh, his uh, uh, employment was terminated, because it uh, he was involved in uh, the war between 2 superstars of (the ?)
One of Dr. DeBakey
and the other one was Dr. Cooley
They were 2 famous, eh, eh, cardiovascular surgeons, who were competing with each other
Ehhh, Dr., eh, the chairman of the department, was on the side of Dr. Cooley, but the boss of, uh, Baylor College was Dr. DeBakey
So after Dr., Dr. DeBakey
learned that, uh, the sympathy of Chairman of the Department; which was Dr. Cooley, his job was terminated
So then they, took another man; very old, professor, who was already retired, to be the chairman of the department
They, he knew nothing about, any type of research (laugh), especially cancer research, and, uh, once I decided to not join the mainstream, Baylor Research Center, eh, the people who are in charge of Baylor Research Center, they put a pressure, on the new chairman of the department, and they frightened him, saying look, you are, uh, in a charge of anesthesiology, but here’s a guy doing cancer research, eh, and see this was a great, uh, like liability to you, and pretty soon he may be sued, uh, without knowing what he’s doing
Ok
So then, uh, they, they, um, brainwashed the old man, and he decided to strip me, slowly from my laboratories, eh, and, and, harass me
Ok, uh, ultimately, he sent me the letter that, uh, in which he informed me that he does not see any connection between, uh, my research and anesthesiology; which was obvious, eh, but obviously I was doing the research which made the university famous, more or less

Yeah

So then one thing to another, and I decided, no, I am not going to work with, in this environment anymore, and I decided to do, try to do on my own, to start my own laboratory
So that’s what happened
Ok

And then you did that ?
You had your own, laboratory ?

Yes, and then I decided, this was just the beginning of 1977, and, uh, e, we put together a laboratory; of course I already had private practice, and, uh, I was still working

In your private practice

Yes

you were still seeing patients ?

Absolutely, absolutely

Seeing any results ?

Yeah, seeing patients, getting results
I began phase I clinical trials

Mhmm

in the hospital where I was seeing patients
I had patients at that time, in about 2 or 3 different hospitals, uh, but the hospital, where I get permission to do clinical trials, was a most supportive, and that’s why I did it this way, and, uh, obviously it was necessary for me to build from scratch, the laboratory, the research laboratory
I decided that I just, uh, I just, uh, make some funds in, our private practice, and at that time, of course, this was just, um, general (?) private practice, internal medicine private practice, em, and, uh, the funds which I produced in private practice I can use to, put together the laboratory, and that’s what we did
Ok
Step by step we build the laboratory, and we expanded our private practice
So basically, I switch from the government and then I found it best to fund the research, just privately funded research, which nothing unusual, thhh, some like 50 years before everyone was doing it

Everyone is doing this

Yes, and there’s still some people, especially in the U.K., who are doing this
Ok

Yeah

Um, the most of the discoveries were made through the, sss, through the research that was funded, by the researchers

Mhmm

There are also some, wealthy people who donated the money to do it
So only after World War II, this was, um, the system was created where, the researchers became, um, really became the slaves so, the government

Mhmm

and pharmaceutical companies, and new companies, and if they do not receive the money, they couldn’t do anything
This way I could have independence, and, uh, do whatever I want
Yes

So at what point did it get to where, action was taken against you, and you knew that you were going to have to go to court ?

The action, um, um, started very soon, and the, and began at the lowest level, which is like, county level, and then you go obviously

Mhmm

higher as you move along, and when, uh, I was leaving, uh, the university, the chairman promised me that (laugh) when I leave, uh, the obviously, quote, unquote, “They will bust my ass”
Ok ?

Yeah

(laughing)

When leaving the university

When I was leaving the university ?

Yeah

Yes
And, uh, he promised me that, uh, they will trigger the action from Harris County’s Medical Society; which is probably the lowest level of harassment and just, the somewhat prestigious society if you are are a good doctor practicing medicine, in Harris County, where Houston is, then you should be a member of the Harris County Medical Society
Uh, if you are not a member of Harris County Medical Socity they won’t grant you privileges to see patients in hospital
So this was important to be a member of the Harris County Medical Society because I was practicing medicine

Why do you think
Why do you think they wanted to stop you ?

Why did’d they wanted me to stop ?

Yeah

Well, probably just for the heck of it
I don’t know

(Laughing: both)

Ok

Well do you think they were threatened by you ?

Well, I doubt it
Their probably some type of revenge
Ehhh, since I didn’t yield to their harassment, and I decided to do whatever I was doing, and decide to do it on my own

Mhmm

and they felt, well, let’s try to kick his behind if we can
Ok

Yeah

Well I don’t think I was, uh, causing any threat to them at all, because this was really, large institution

So it escalated ?

Yes
Just starting at the lowest level
It was, eh, unpleasant because they were dragging me to like, holy inquisition proceeding, explain what I was doing, and basically they’re trying to force me to stop what I was doing by using various ways
Obviously they didn’t have any, uh, reason to do it because, uh, my clinical research; which I was doing in the most, done under the supervision of, Institutional Review Board, and before I started anything I asked, uh, I retained medical lawyers, and I asked them to check, if I can, uh, for instance, do the research to use medicine, and use it, in a patient, and they
checked with this, State authorities, Federal authorities, and at that time it was perfectly alright
So I was doing, everything, legally
So, they really couldn’t do much, but, they were harassing me, asking for me to give them a lot of documents, whatever, and suddenly, all of it stopped
It stopped because they were exposed by news media

Yeah

So, when the article was written about it, they disappeared from, the horizon, and then they never, harass me since then (laugh)

Yeah

I think it’s, lasted probably for, 2 or 3 years, and then it was gone, so

And then, and then how did that end up ?
How did you end up going to court for the 1st time then ?

Oh well, so obviously there was no, uh, issue of going to court at that time, it was only the issue that, I might not be a member of, uh

But you might not have been able to practice medicine

the medical society, and then I would not be able to see patients in the hospital
Ok
So this was deliberate, ok, and at that time, m, most of my patients were treated in the hospital, because I didn’t have yet the system to use treatment outside the hospital, like for instance the pumps that we are using now
They did not exist at that time
So it was necessary to use I.V. posts

Mhmm

and, uh, and heavy pump, heavy treatment
So then, uh, so this was, uh, it started around ’78, it continued for a couple of years, and then nothing happened after that
I was visited by, um, FDA people, but we have pretty constructive meeting
They didn’t bother me, and, uh, the next attack occurred in a 1983, and this was by, uh, Food and Drug Administration
So, suddenly I was sued, and, um, they really wanted to put me out of business
Ok

They didn’t just want to put you out of business
I mean, they wanted you, they wanted you to go to prison

No, in ni, 1983, they wanted me out of business

Right, just out of business

Yeah

Don’t want you practicing

Shut down, what I am doing, and they did it, secretly (laugh)
Most of this actions occurred around, uh, just before say Passover, and Easter
Ok

Yeah

Every year
It never failed
Ok (laughing), a, and a usually they were attacking, uh, uh

Someone

No, no
For instance it happened for instance I was away, and, uh, they were filing papers in court, like, um, around 5 p.m. on Thursday, ok, and Friday was day off, because was big Friday, Good Friday
Ok
So then, obviously, um, they then
realized I’d be away because I participated in some T.V. program, and they want to do it while I was away, but, uh, it so happens that
a one of the friendly lawyers was in court at the time, and he overheard whatever they were doing, ok (laughing),they were going for injunction, ok, and so then, uh, I would be stopped immediately
I wouldn’t be able to do much, ok, until the judge would reverse it, but, uh, he read about it and he prepared immediately temporary restraining order, and filed at the same time (laughs)

Yeah

So then, uh, I could practice without any interruptions, but, uh, then, of course,

So do you think of all the people that were trying to stop you

Yeah

Do you think any of those people actually, really, genuinely believed that you were causing harm to people

Hmmm

or do you think that they were just stopping you because ?

I think some stupid people,was at the lower level, like, uh, uh, some lower level FDA agents, they didn’t know what they were doing
They were manipulated, ok, but the guys who above, they knew very well (laughs) that, I was right

They knew what they were doing

Absolutely

They knew you were doing something

Absolutely, yes

groundbreaking

They knew very well, and that’s the reason why they attack me
Ok
Yeah
It’s obvious
So this 1st encounter, was relatively brief
Uh, we went to court, which was Federal court, and the judge, uh, would rule in our favor, and the judge, uh, uh, in the verdict, uh, cleared me from any, of the charges, and, uh, I found that I could, uh, I could treat anybody, by using my methods, but I cannot really, uh, sell medications outside the State of Texas, and that’s what I was not doing anyway
So really,
the judge
affirmed what I was doing

Right

That I’m free to use my invention, and treat people in the State of Texas, which made, of course, the government, uh, people furious, and they threatened the judge
They send the judge a letter saying that, if the judge will not rule their way, then they will go after me with criminal investigation, uh, with seizures, uh, eh, grand jury investigation
That’s what they did as the next step

When was the next step ?
How many years later was that ?

Well again, there was some like couple of years when it was relative quiet
Of course, in order to be, eh, in, eh, in order to do what I was doing, it was necessary for me to have inspection, by the inspectors, approved by the FDA, who
check our manufacturing facility, and, ah, certify that what ever we do, we do right, and there are no discrepancies
So this was obviously something, very difficult, because obviously we knew that the FDA inspectors
will always find something wrong, you know

Yeah

So these agents are trained to always find something wrong, but anyway, at inspection, uh, found we are doing everything perfect
Ok (laughs)
So we were able to pass the inspection
Uh, we are in full compliance with what is called good manufacturing practices, and then everything was quite until about 3 years later when, uh, there was a raid on our clinic by the FDA, and seizure of, ah, medical records, and then there was another, uh, obviously, ah, another, uh, part of the war began, and then, uh, we file a lawsuit against FDA, and, uh, as a result the judge forced the FDA to give back some, of the documents, and permit us to, uh, be able to copy the rest of the documents, and so then, uh, FDA began a grand jury process, and, uh, there was some, like 4 different grand juries, uh, ah, which did not find me, guilty of anything, and then finally 5th grand jury was able to indict me, which was in ’95
Ok

So when you were, when you were going to court; because I remember seeing in the

Yeah

Burzynski, the movie

Yes

I remember seeing in the photographs

Yeah

around here

Sure

there were lots and lots of people outside there (?)

Yeah

What was that like to see that ?

Oh well, ah, this was, uh, going for ever, going to court, and obviously I was going before this grand jury investigation, whatever, but ultimately, their lawsuit, uh, the trial began, in, ah, January of ’96, and, uh, it took a number of months
Ok
So I was going to court almost every day, and the people realized what was going on, and they were giving us a lot of support
So then you can see people outside the court

What was that like to see your patients ?

Well it was, ah, it was, ah, very good, uh, uh, show of (laughs)

Yeah

patient solidarity
They wanted obviously, to help us, and they knew that, uh, they have the power, and, uh, they knew that they were fighting for their lives
Ok ?
So they, uh, were dedicated people
It wasn’t easy because this was winter, and it was raining, and so it was cold weather, but obviously

Were you prepared to, to face what you could have faced, you know, that you actually could have gone to prison ?

Sure, yes
I, I knew, but I was, convinced that I am going to win
So, should I, obviously, statistically it was, uh, highly unlikely, but, uh (laugh)

Do you think that this will stop one day ?

That people will just get off your back, and (laugh)

(laughs)

you know

(?)

and can see what you’ve done

(?)

and, and see that there’s really something there

Absolutely

This is just the (?)

Absolutely, absolutely
I
That’s what I was convinced was going, to happen, and, uh, I was convinced that we are going to win, with FDA

Good, ’cause I mean, anyone does any research

Yeah

you know
I had this on here

Yeah, sure

which I’m sure you’ve seen, like on Wikipedia

Yeah

and what it says
That there’s no convincing evidence

Yeah, sure

that a randomized controlled trial has, you know
That your work, that, that there’s nothing there

Yeah

What’s that like when you come across that stuff
Do you just not read it, and just

So (laughs)
Simply don’t pay attention to it, because it, it’s not true
Ok

Yeah

You won’t be able to, do any, clinical research which we do, without convincing evidence, especially when you have the most powerful agency in the government which is against you

They’re against you, but you’ve been working with them for, for

Yes, so since 1997
Yes, but you see

Yeah

Obviously they didn’t have any sympathy to us because they lost
So they would love to find something which is wrong with what we are doing
They would love to prove that the treatment doesn’t

Yeah

So this is, very difficult
Ah, so the fact that they’ve, um, agreed that what we have has value, and they allow us to do phase 3 clinical trials, it means that we are right
Ok ?

Yeah

Because, uh, uh, nobody who didn’t have any, concrete evidence that it works, would be able to go as far
Ok

Yeah

So whatever Wikipedia says, well, I don’t care for them (laughing)

Ok, so, we, we talked a little bit about, what you, where you’ve come from, and what you’ve been through
As far as your treatment, um, to cancer, and this I’m very interested in, and why you don’t think high doses of chemotherapy is, is particularly helpful for the body, and what

Well it is generally wrong approach
It can help, some patients, wi, with a rare form of cancer, but only, eh, in limited capacity
Those who, are quote, unquote “cured”, usually die later on from adverse reactions, of chronic adverse reactions from chemotherapy or radiation, or they develop secondary cancer
So certainly, there is, this is not such a cure which you have in mind, that, use the treatment, patient recovers and lives normal life
Such cure does not exist for patients who are taking chemotherapy or radiation
They will always suffer, some problems
Either from cancer, or radiation, chemotherapy, and there is only small minority of patients who have advanced cancer who can, have long term responses
So obviously, this is unacceptable treatment
Of course, it was important at certain stage of development, but now, of course, uh, when we know more about cancer, it’s becoming, uh, unacceptable, and I think it will disappear, from the surface of the earth, in another 10 years, or 15 years, and, uh, in the medical textbook, this will be described as strange period of time, when people were using some barbaric treatment
Ok

Mmm
You have a number of different ways of treating cancer
So, one of them is the antineoplastons

Yes

This, this, this is the peptides

Mhmm

The, the this is the thing that my partner is on at the moment

Sure

in the clinical trial, and, uh, you’ve had some real great success

Mhmm

using that
Right ?

Yes

But you also have

Mhmm

another way, of, of, of treating, which is, using, it’s using some sort of chemotherapy, but in low doses

Well, um, um, whatever we are using we are using treatment which works on the genes

Antineoplastonswork on the genes, and they work on about 100 different genes

So what are they doing to the genes ?

Well, they work as molecular switches
They turn off the genes which are causing cancer, and turn on the genes which are fighting cancer
So, that’s what they do, and they produce this in about 100 different genes
It’s not enough, to control all cancer
Actually you can control some cancers, but not all of them, because you may have, numerous genes involved, in cancer
Well, for instance, in average case of breast cancer may have 50 abnormal genes involved
Uh, in, uh, like grade 3 brain tumors, for instance, anaplastic astrocytoma you might 80, or might be 100, but if, uh, you go to highly malignant tumors like, glioblastoma, you have, probably about 550
Eh, if you don’t cover such a spectrum of genes, you won’t, you’re not going to have good results
So that’s why, we know from the very beginning that we have some limitations
We can help some patients but not all of them, because, they have involvement of different genes which are causing, their cancer
So then you can still have these patients who are combining the treatmentof antineoplastons,with different medications which are in existence, which work on different genes, and this includes also some chemotherapy drugs, which are available
Eh, so this means that, um, for the patients for whom we, cannot use antineoplastons, because they are not in clinical trials, then we are using combination treatment, which consists of medication which already, approved as prescription medications, and, uh, by using the right combination by knowing which genes we need to attack, we get much better results
Now this also includes chemotherapy, but we never use, high-dose chemotherapy
If necessary, we use low-dose chemotherapy, and when you use low-dose chemotherapy you don’t have, uh, toxicity, which is, bad
We use this for
patients continuously, without much problem

So, so one of the main reasons of using low-dose chemotherapy is to try and keep your immune system strong, as well ?

No, to try to quickly decrease the size of the tumor, in combination with the other medications
We can use, for instance, low-dose chemotherapy and another medication which will increase activity,of chemotherapy, and as a result, you can have, as good, uh, uh, decrease of the tumor, with the low-doses

when you use heavy-dose
Well, there’s nothing unusual about it
For instance, uh, many doctors are using medications which are quite toxic

Mmm

And they, if they use the dosages, it’s helpful to the patient
The question is, what dosage will you use ?
If you use the dosages which are not toxic, it may still help the results, for instance, eh, the medication which was introduced, in mid, uh, 18th century for a particle for heart failure, in U.K. by
Dr. Withering, which was digitalis extract
Obviously it was highly toxic medication
It can kill people, in dosages much smaller than chemotherapy, but if you use the right dosage, it can help people
It was helping people for over 200 years
So those are the question
What kind of dosage do you use, and what combination do you use, and then, it can be useful

How did work that out then ?
I mean, how did you work out

Mhmm

that using small dosages of chemotherapy, could be effective ?

Uh, well, uh, it’s not only based on, uh, our research, it’s based on the research of the other, doctors
There are numerous publications on the subject, and in many cases the low-dosages can be used more effective than high-dosages, and, uh, on the other hand, by doing genetic testing, we can identify, which, uh, medications are the best for the patient

‘Cause you use

(?)

’cause you use a lab, in Phoenix
Right ?

Correct, yes

And, and how did you find out about them ?
Um, how did you ?
Yeah

Well, uh, uh, frankly speaking (laughs), 1st time I find about it by, treating patients who’s referred to us by one of the best oncologists in the country
He was usually treating some movie stars (laughs)

Yeah

and I found that this patient had, uh, genetic testing done, and I got interested in this, and I found about this laboratory
It was some time ago, but anyway, while we were doing genetic testing before, but, uh, we didn’t use this laboratory yet, we did it, through some other laboratories, and such testing was much, much simpler
So, we are using such testing, for a number of years, but in the capacity we are using now, this is really the last 2 to 3 years

So what happens is someone’s, bit of their tissue gets sent off to this lab ?

Yeah, the tissue is sent to the laboratory, and, uh, they do, testing on the entire genome of 24,000 genes
They identify the abnormal genes, and they go in-depth, by studying what happened to these genes?
Are they mutated ?
Are they amplified ?
And then from this, we have, a lot of information, and ultimately we like to know, which medications we can use to treat genes
What we are doing, we are treating genes, rather than, the tumor, as such

Mhmm

And, uh, if you identify all the genes that are involved, and find out which medications we can use, we can have very good results

And that’s what you found ?

That’s right

So in some case you’re treating people that might have a certain type of cancer

Yes, mhmm

with a drug that was designed for a different type of cancer

Uh, that’s right, because we are treating the genes, and, uh, if you find out that, this particular patient has, uh, an abnormal gene, which is not typical for this cancer but we have medication

Hmmm

that works on this gene, that’s what we use

So I would imagine that to treat, uh, that to treat people, this way, is obviously the future
Everyone’s different
Everyone’s genetics are d, d, different

That’s right

genetic markers, but to treat them that way, would require a bit more work

That’s, uh, obviously (laughs) (a life’s ?) work
Uh, uh, we’ll, like, uh, not just simply for, eh, uh, 4 different types of lung cancer

Yeah

Maybe 100,000 different types of lung cancer, each with, different, uh, genetic signature, ok, and once you identify this, then you can treat, such patients logically, and have good results, and if you do it on the scale of, uh, the entire country, this would, uh, give you much better results, and, uh, great savings, because

Mmm

you won’t use expensive medications for everybody, but perhaps for 10% of the population, and then for this 10% of population is going to work

Yeah

Which means that these people will avoid disability
They won’t spend time in the hospital
Uh, they will have short course of treatment, and then they go back to work
So the government would understand, uh, that’s something that can give them a lot of savings
I think they will go for it
Eh, gene testing, eh, at this time is still, uh, relatively expensive
It’s covered by, uh, the insurance of the United States, but for people outside, may cost 5500 euros, for instance, but I think it will be substantially less expensive in the near future
I think it will be below $1,000 for complete testing
So for running the test, uh, uh, eh, and, uh, finding out which treatment, has the best chance, you can save, 100’s of 1,000’s of dollars for individual patients

Yeah, but obviously pharmaceutical companies probably wouldn’t be too happy about that

No, no

People aren’t going to be taking their medications anymore

Well obviously be mostly happy that they can sell a lot of medications, but some of them are beginning to pay the attention, because they have to, because if they don’t, their competitors, will pay the attention

Mmm

Obviously, they would like to have, possibly, the best possible results, in clinical trials, so now they begin to screen population of patients for clinical trials, and do some limited, genetic testing, but, so, of course, they do it, uh, for the better of clinical trials so have best results

Yeah

Doesn’t mean that they’ll do, do it when they sell medicine, to millions of people commercially
They may forget about mentioning this medicine works the best for

Yes

this population of patient (laughs)

So what’s your, your vision ?
Wha, wha, what do you, striving to achieve ?

Well what I am trying to achieve is to introduce the way we treat patients, in, in various countries in the world, and, uh, what this would accomplish is, 1st of all, much better results of the treatment, much simpler treatment where perhaps only 1% of patient would need hospitalization, which would, uh, result in great savings
Uh, the treatment, uh, will be done for shorter period of time
For instance, few months to get rid of the tumors, then, uh, perhaps a year, to stabilize the results, and then go back, working and living, ok, without cancer
This, uh, genetic, genomic testing would be absolutely done for every patient who will come for treatment, to identify, what is the best treatment combination indication
So that’s what I would like to foresee, and then, of course, um, immediately, you substantially reduce, the expenditures for medical
For instance, if, you assume that in the mid, medium-sized country, will spend, for instance, a billion dollar, for, socialized medical treatment which will coincide with hospitalization
Ok
Uh, then, uh, most of the cost is for hospitalization, and services necessary for keeping the patient in hospital, then treating adverse reactions, which are, occurring because of the poor selection of medications
Eh, then if you switch to the outpatient treatment because you use medications which are not going to give such bad, side-effects, because you select this medication based on genomic testing, ok, and then immediately instead of a billion dollars a year, you cut down your expenditures to about $100,000

Yeah

100 million dollars
Ok ?
Probably slash it 10 times
Ok ?
And then people will be happy because, ah, the don’t need to stay in the hospital for a long time
They have less adverse reactions
They can go to back to work, much sooner
Ok
So that’s what I, can foresee as, the treatmentin the future
Not really hospital-based treatment

Mhmm

for patients, and most hospitalization is required because of adverse reactions from chemotherapy, radiation, but outpatient treatment, much easier treatment, also
medication given in tablet forms, for instince

And that’s what you’re doing here, right ?
I mean

Correct, yes correct
Usually in hospital, only, perhaps, for, one or two percent of patients, and, we would like to avoid it because when the patient goes to the hospital, he can pick up, some in-opportunistic infection, and then we are talking about more problem
Of course, I believe detection of cancer will be very important, because you don’t want to, uh, have a patient who is so advanced that he is fighting for, life, and he needs to be in the hospital
Ok

Yeah

If you had diagnosis in the early stages, then the patient does not need hospitalization
He can be treated very easily, then go back to work
So that’s the issue
And of course prevention is another important issue to us
To identify, changes in the body, which may indicate that the patient has already, early stages of cancer, also based on genetic tests, and get rid of this by using, behavior modification, by using proper diet, by using supplements, whatever, even without any medications

So, you’re obviously very passionate about what you do
Right ?
That, that’s my question about that

Well, I think it can help s, people in a great way, and, uh,

Well it can, I mean

Yeah

You have had so many su

Yes

I mean, I was talking to my girlfriend

Yeah

the other day,

Yeah

I mean, people, you know, you hear people say, this is a scam, and I was thinking, well the, if it is a scam

Yeah

it has to be one of the biggest scams ever

(laughing)

because all you’ve gotta do, is look on the walls

Yeah

and you look at those photographs

Yeah

Perhaps, this won’t surprise you
I’ve spoken to some oncologists just in the U.K., and they say, all of these people that you have helped, they either ever had cancer in the 1st place

Mhmm

or they were misdiagnosed

Yeah

or, uh, they went into spontaneous remission

Yeah, well

or they, it was the chemotherapy or radiation

These people, they don’t know what they do
They never, have never seen our results, and obviously they can’t believe that something like this could happen, but suddenly (laughs), in this room we are in now, we have some of
the top experts in the country, like people from FDA, who are expert oncologists, specialists

They’re working with you

Oh, they came here to inspect what we have

Yeah

They look at every scan of the people who are in clinical trials, and they decided that we have very good results

And is that stuff going to be published at some point ?

Ah, yes, we are publi, we are preparing this for publication, but, uh, obviously, in order to have the right results, you need, time, and most of our clinical trials began, approximately 10 years ago
So then we, if you would like to know what happen after, 10 years with these people

Mhmm

then you need to have a little time
So now we are preparing a number of, uh, publications, uh, and so this year we should have a number of publications, which will show final results
So far we didn’t have, final results, so were only interim reports, during the course of clinical trials

And with, uh, with brain tumors; because obviously, that’s an area that you’ve had

Yeah

huge suc, success rate

Yeah

What, why has that, do you think, as opposed to the other, types ?

Because that’s where we selected

Mhmm

We wanted to have something difficult
Ok (laughs)

Yeah

Because, uh, for the same reason that you mentioned
If you’d had something easier then, the doctors could say: “Well, this cancer usually disappears in its own”
And they are right
Some cancers may disappear on its own, in some higher percent than the others

Mhmm

But you know, brain tumors, you read, they never disappear on their own

Yeah

So that’s why we, decided to select such type of malignancies which are the most difficult

So what’s that been like when you’ve seen, I mean, I’ve seen obviously Jodi Fenton’s story

Yeah

Whe, whe, when you see these people’s

Yes

uh, scans

Yeah

and you see that that tumor has shrunk

Yeah

or broken down

Yeah

wha, what does that feel like ? (laughing)

Well, we see this all the time
(?) it just happens almost every day
Even today that we saw the patient, uh, who has pancreatic cancer, and after a few months of treatment it’s practically gone, and she is the wife of a doctor (laughs)
They came together, and that’s, that’s what we see practically every day
Ok

That must give you great strength to

Absolutely

continue

Absolutely, yes
So that’s something which is gratifying (laughs)

Yeah
What do you think the future is as far as drugs for cancer are concerned ?

I believe that, we are still at a very early stages of development in this area, but the future will be, with medications which are, highly specific, they will work on the genes that are involved in cancer
So, they will not harm normal part of the body, and, du, du, how to combine this medications will be established by, the special software, which will guide the doctors how to use proper medication for individual patient
I think this will be the, um, treatment that will be designed for, individual patient, and such design, it is not necessary to be done by the doctor
I think it should be, uh, certain computerized system which will put together, the best possible treatment plan, for a patient; which obviously needs to be checked and approved by the doctor
So I believe that this will be the future of medicine for the next, say, 40, and 50 years, coming up with better and better medications, which will be genomic switches, which will turn off, the cancerous process by regulating the genes which are involved; they simply will bring, the activity of these genes to normal levels, and finally, the new generation of medication which should work on cancerous stem cells, and, the medications which can kill cancerous stem cells without, uh, producing any harm to normal stem cells
So this will be the clue for, long-term control of cancer, because if you don’t eliminate, cancerous stem cells then the cancer will come back

Yeah

And that’s why chemotherapy, usually is unable to control cancer for a long time because, it’s pretty much powerless, ah, uh, regarding action on cancerous stem cells
But then after that, I think that we will make another, jump, and there will be, uh, procedures that will based on biophysics

Mmm

and by trying to get rid of, uh, the cancer and some of the diseases by effecting the body by using various, uh, wipes, which will be like magnetic wipes, it will be some other types of wipes, but using proper frequencies to, normalize all the cells in the body to normalize the activity of the genes
I think this will be a

Mmm

probably the next, uh, say 50 years of, uh, the end of this century when such (?)

So no one’s getting funding really, unless they’re doing it privately to,
being able to, isn’t that being able to research these areas, because funding really comes from pharmaceutical companies ?

Ah, well, most of this funding is from pharmaceutical companies, and also it is coming from the National Cancer Institute but, I think it’s regulated behind the scenes by the pharmaceutical companies
Eh, but they are still some researchers who are trying to do it on their own
Very few of them
I think there’s articles, in the Science magazine, some time ago which was talking about, uh, few of these researchers who are still trying to do, research on their own, and, I think, uh, I think there were probably some 4 or 5 of them in U.K. (laugh)

Yeah

still involved in research on their own

So what ah, what about the role of the mind ?
Do you think that, if someone has cancer and they wanna be well, do you think the way that someone thinks is important ?

Absolutely, that’s very important because, this, uh, can be translated, ah, to various biochemicals which can influence cancer
So obviously this is very important but, the question is how to, ah, direct this in the proper way
Ok
How to quantify this
So that’s something that should be done in the future

And nutrition as well

Yes, absolutely, yes
Why all have a lot of important chemicals in nutrition which can effectuate cancer, but regarding the mind you have to translate, uh, for instance, biophysical factors, in the brain, into biochemical factors, and certainly, that’s what the body’s doing all the time, but how to mobilize it, that’s a different story
Yeah

So if someone wants, if someone came to the Burzynski Clinic, wh, wh, what could they expect, to happen here?

Well 1st of all, we would like to give a selection, and we don’t want the people who we cannot treat to come
Uh, at this time we rather avoid, uh, patients in early stages of cancer, because with such patients, uh, what is used is standard of care treatment, and we prefer to refer them to, ah, different doctors
So we prefer to treat it once cancer patient, because, uh, they cannot be helped by the other doctors, and, uh, when they come to our clinic, we try to find out 1st, see if we can really help them or not, and, uh, once they come to the clinic, in most of the cases we can try to, help them, of course, and, uh, we put together, the personalized treatment plan, which is (?)

But all of those go through you
You look at every single one of those

Yes
I’m seeing every patient, who’s coming, if I’m

Yeah

if I’m around here, but, after that all the patients are really assigned to different senior physician and they’re responsible for daily care of patient here

How many people do you have, working here now ?

About 150 people here, yes

And you started with, well, just one (?)

Eh, I think really when we moved from Baylor College I had about 7 people at that time

Yeah

Yes, because, some of these doctors who are working together at Baylor College decided to leave together with me, including my wife, because she was also working at Baylor College

Yeah

Ok

Thank you

You’re welcome
My pleasure

Thank you so much

Thank you very much
Ok
======================================

======================================

Critiquing David H. “Orac” Gorski, MD PhD and his Personalized MUD-Targeted Skeptic Therapy

Posted on by
Reply

I’ve made no secret of my opinion of a certain cancer “research” doctor named David H. Gorski, MD, PhD, of Wayne State University School of Medicine and Barbara Ann Karmanos Cancer Center / Institute, Detroit, Michigan fame

Gorski, as you may recall was responsible for this 6/3/2013 “Orac” posting:
======================================
In which the latest movie about Stanislaw Burzynski’s “cancer cure” is reviewed…with Insolence
——————————————————————
http://scienceblogs.com/insolence/2013/06/03/in-which-the-latest-movie-about-stanislaw-burzynskis-cancer-cure-is-reviewed-with-insolence/
——————————————————————
Critiquing: In which the latest movie about Stanislaw Burzynski “cancer cure” is reviewed…with Insolence:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/07/18/critiquing-in-which-the-latest-movie-about-stanislaw-burzynski-cancer-cure-is-reviewed-with-insolence-2/
======================================
When last we left Gorski, his propaganda, which I characterize as pure propaganda so incompetently made that it would make blush blush

After a couple of winks I changed my characterization to say that it would have made Penn and Teller vomit in revulsion at its sheer incompetence

Be that as it may, I view Gorski as highly unethical and pseudononsense, an incompetent purveyor of “personalized MUD-targeted medicine for dummies,” and someone who might at one time have been on to something but, like all hacks, just couldn’t let go when it became clear that his personalized MUD-targeted Skeptic therapy was far more toxic than advertised and way less efficacious, if it’s even efficacious at all, which is highly doubtful.

Gorski claimed:

“[I]f I had screwed up, I would have admitted it”

Data talks

BS walks

And there’s no doubt that Gorski, too, is pure BS

In fact, I think I’m being too kind

I have yet to see his admission that he lied when he posted:

“how Burzynski never explains which genes are targeted by antineoplastons … “
======================================
Critiquing: Dr. David H. “Orac” Gorski, M.D., Ph.D, L.I.A.R.:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/08/07/critiquing-dr-david-h-orac-gorski-m-d-ph-d-l-i-a-r/
======================================
8/12/2013 Gorski blogged:
======================================
A study of antineoplastons fails to be published. Stanislaw Burzynski’s propagandist Eric Merola whines about it. News at 11.
——————————————————————
http://scienceblogs.com/insolence/2013/08/12/antineoplaston-fails-publication/ ======================================
In regards to antineoplastons, Gorski states:

“antineoplastons are chemotherapy”

“They even have significant toxicity!”

What science based medicine publication(s) does Gorski cite in support of his “theory”?

NONE !!!

What do the science based medicine publications indicate?
======================================
[1] 4/1/1992 PHENYLACETATE-novel NONTOXIC inducer of tumor cell differentiation
——————————————————————
Sodium PHENYLACETATE found to affect growth and differentiation of tumor cells in vitro at concentrations achieved in humans WITH NO SIGNIFICANT ADVERSE EFFECTS
——————————————————————
PHENYLACETATE is effective in inducing tumor cell maturation and FREE OF CYTOTOXIC AND CARCINOGENIC EFFECTS, a combination that warrants attention to potential use in cancer intervention
——————————————————————
Sodium PHENYLACETATE is investigational new drug approved for human use by U.S. Food and Drug Administration
——————————————————————
DRUG ALREADY ESTABLISHED AS SAFE AND EFFECTIVE … we propose use may be extended to cancer preventation and therapy
======================================
[2] 8/20/1992 Difficulties may be overcome through exploitation of recent discovery of sodium PHENYLACETATE as NONTOXIC inducer of differentiation …
——————————————————————
(pro-drug) Sodium 4-PHENYLBUTYRATE can be given in oral doses of 0.3 to 0.6 g per kilogram of body weight per day with NO ADVERSE REACTIONS
——————————————————————
Drug rapidly metabolized to PHENYLACETATE and PHENYLACETYLGLUTAMINE
——————————————————————
PHENYLACETATE (but not PHENYLACETYLGLUTAMINE) … CAN POTENTIATE EFFICACY OF OTHER DIFFERENTIATING AGENTS, such as cytotoxic drugs …
======================================
[3] 9/15/1992 we explored efficacy of PHENYLACETATE, an amino acid derivative with LOW TOXICITY INDEX WHEN ADMINISTERED TO HUMANS
——————————————————————
PHENYLACETATE, used alone or in combination with other drugs, might offer safe and effective new approach to treatment …
======================================
[4] 5/1993 NONTOXIC differentiation inducer, sodium PHENYLACETATE (NaPA)
——————————————————————
In vitro antineoplastic activity was observed with drug concentrations that have been achieved in humans with NO SIGNIFICANT TOXICITIES, suggesting PA, used alone or in combination with other antitumor agents, warrants evaluation in treatment of advanced prostatic cancer
======================================
[5] 10/1/1993 Sodium PHENYLACETATE (NaPA) and its precursor, sodium 4-PHENYLBUTYRATE (NaPB), can enhance HbF production in cultured erythroid progenitor derived from normal donors and patients with SS anemia or beta-thal, when used at pharmacologic concentrations
——————————————————————
NaPA and NaPB, BOTH ALREADY PROVEN SAFE AND EFFECTIVE IN TREATMENT OF CHILDREN …
======================================
[6] 2/15/1994 sodium PHENYLACETATE can induce cytostasis and reversal of malignant properties of cultured human glioblastoma cells, when used at pharmacological concentrations that are WELL TOLERATED BY CHILDREN AND ADULTS
——————————————————————
Systemic treatment of rats bearing intracranial gliomas resulted in significant tumor suppression with NO APPARENT TOXICITY to host
======================================
[7] 4/1/1994 Pg. 1690
——————————————————————
protocol underwent several modifications over 6-month period
——————————————————————
Interest in PHENYLACETATE as anticancer agent generated by reports that ANTINEOPLASTON AS2-1, a preparation which by weight is 80% PHENYLACETATE, displayed clinical antitumor activity (13)
——————————————————————
17 patients (16 men / 1 woman) (36-75) median age 57
——————————————————————
Pg. 1693
——————————————————————
Clinical Toxicities. NO TOXICITY associated with bolus administration of drug
——————————————————————
Drug-related TOXICITY clearly related to serum
PHENYLACETATE concentration
——————————————————————
3 episodes of Central Nervous System (CNS)
TOXICITY, limited to CONFUSION
and LETHARGY and often preceded by emesis, occurred in patients treated at dose levels 3 and 4
——————————————————————
Symptoms resolved within 18 h of terminating drug infusion in all instances
——————————————————————
Pg. 1694
——————————————————————
PHENYLACETATE serum concentrations … were typically associated with CNS toxicity
——————————————————————
While ability to cross blood-brain barrier may underlie clinical improvement seen in patient with glioblastoma, could also explain dose-limiting side-effects of drug, i.e., nausea, vomiting, sedation, and confusion
——————————————————————
Limited experience with 150-mg/kg i.v. boluses suggests serum PHENYLACETATE concentrations occurring transiently
above 500 ug/ml are well tolerated
——————————————————————
Intermittent drug infusion should permit some drug washout to occur, thereby minimizing drug accumulation
——————————————————————
Predicts wide range of peak drug concentrations will be observed
——————————————————————
Possible these would be sufficiently transient so as not to produce CNS toxicity and troughs not prolonged as to abrogate antitumor activity of drug
——————————————————————
Dosing alternatives should be explored, our study indicates PHENYLACETATE can be safely administered by CIVI and result in clinical improvement in some patients with hormone-refractory
prostatic carcinoma and glioblastoma multiforme who failed conventional therapies
======================================
[8] 6/1/1994 PHENYLACETATE is naturally occurring plasma component that suppresses growth of tumor cells and induces differentiation in vitro
——————————————————————
Treatment with PHENYLACETATE extended survival … WITHOUT ASSOCIATED ADVERSE EFFECTS
======================================
[9] 9/1994 PHENYLACETATE, NONTOXIC differentiation inducer, can suppress growth of other neuroectodermal tumors, i.e., gliomas, in laboratory models and humans
======================================
[10] 4/1995 PHENYLACETATE, an inducer of tumor cytostasis and differentiation, shows promise as RELATIVELY NONTOXIC antineoplastic agent in models and humans
======================================
[11] 6/15/1995 Growth-inhibiting and differentiating effects of sodium PHENYLACETATE against hematopoietic and solid tumor cell lines has aroused clinical interest in use as anticancer drug
——————————————————————
In Phase I trial of PHENYLACETATE … commonly resulted in drug accumulation and REVERSIBLE DOSE-LIMITING NEUROLOGIC TOXICITY
——————————————————————
18 patients
——————————————————————
DOSE-LIMITING TOXICITY, consisting of REVERSIBLE CENTRAL NERVOUS SYSTEM DEPRESSION, observed for 3 patients at 2nd dose level
======================================
[12] 10/12/1995 aromatic fatty acid PHENYLACETATE, a common metabolite of phenylalanine, shows promise as a RELATIVELY NON-TOXIC drug for cancer treatment
======================================
[13] 10/1995 investigated effects of a NONTOXIC differentiation inducer, PHENYLACETATE (PA), on neuroectodermal tumor-derived cell lines
======================================
[14] 1995 Antineoplastons, firstly described by Burzynski, are naturally occurring peptides and amino acid derivatives which control neoplastic growth
——————————————————————
toxicological study of Antineoplastons A-10 and AS2-1 in combination with other anticancer agents or radiation in 42 patients
46 tumors with terminal stage cancer
——————————————————————
Antineoplaston A-10 oral formulation
14 – patients
A-10 injectable formulation
25 – patients
——————————————————————
Antineoplaston AS2-1 oral formulation
33 – patients
AS2-1 injectable formulation
10 – patients
——————————————————————
Major adverse effects that may have been related to agents used in combination with other conventional chemotherapeutic agents or radiation:
liver dysfunction
myelosuppression
general weakness
THESE EFFECTS WEREN’T SEEN WHEN EITHER ANTINEOPLASTON WAS ADMINISTERED ALONE
——————————————————————
MINOR ADVERSE EFFECTS OBSERVED IN SINGLE USE OF EITHER ANTINEOPLASTON A-10 OR AS2-1:
reduced albumin
increased alkaline phosphatase
increased amylase
reduced cholesterol
peripheral edema
eosinophilia
fingers rigidity
excess gas
headache
hypertension
maculopapullar rash
palpitation
adverse effects didn’t limit to continuation of either agent
——————————————————————
Antineoplaston A-10 and AS2-1 LESS TOXIC THAN CONVENTIONAL CHEMOTHERAPIES and useful in maintenance therapy for cancer patients
======================================
[15] 1996 Antineoplastons, first described by Burzynski, are naturally occurring peptides and amino acid derivatives which control neoplastic growth
——————————————————————
reported cytostatic inhibitory effect of A10 on human hepatocellular carcinoma cells and differentiation inducing effect of AS2-1 on various tumor cells suggest potential benefit for treatment of human hepatocellular carcinoma since tumor recurs frequently despite initial successful treatment
——————————————————————
Clinical experience of hepatocellular carcinoma (HCC) patient whose tumor, after incomplete trancathere arterial embolization (TAE) for a 7cm 7cm HCC, has been stable for more than 15 months during which time he has been taking Antineoplaston AS2-1 continuously WITHOUT ANY SERIOUS ADVERSE EFFECTS
======================================
[16] 5/1996
——————————————————————
In pursuit of alternative treatments for chemoresistant tumor cells, tested response of multidrug-resistant (MDR) tumor cell lines to aromatic fatty acids phenylacetate (PA) and phenylbutyrate (PB), 2 differentiation inducers currently in clinical trials
——————————————————————
Both compounds induced cytostasis and maturation of multidrug-resistant breast, ovarian, and colon carcinoma cells with no significant effect on cell viability
——————————————————————
MDR cells generally more sensitive to growth arrest by PA and PB than their parental counterparts
——————————————————————
PA and PB potentiated cytotoxic activity of doxorubicin against MDR cells
——————————————————————
Taken together, in vitro data indicate PA and PB, differentiation inducers of aromatic fatty acid class, may provide alternative approach to treatment of MDR tumors
======================================
[17] 12/1996 PHENYLACETATE (PA) and related aromatic fatty acids constitute novel class of RELATIVELY NONTOXIC antineoplastic agents
======================================
[18] 8/1997 aromatic fatty acids PHENYLACETATE (PA) and PHENYLBUTYRATE (PB) are novel antitumor agents currently under clinical evaluation
————————————————————
ability to induce tumor differentiation in laboratory models and LOW CLINICAL TOXICITY PROFILE makes them promising candidates for COMBINATION WITH CONVENTIONAL THERAPIES
======================================
[19] 1997 PHENYLACETATE and analogs represent new class of pleiotropic growth regulators that alter tumor cell biology by affecting gene expression at both transcriptional and post transcriptional levels
————————————————————
Based on findings, NaPA and NaPB entered clinical trials at National Cancer Institute
————————————————————
Ongoing phase I studies with NaPA, involving adults with prostate and brain cancer, confirmed therapeutic levels can be achieved WITH NO SIGNIFICANT TOXICITIES, and provide preliminary evidence for benefit to patients with advanced disease (Thibault et al., submitted)
======================================
[20] 10/1997 Sodium PHENYLACETATE (PA) and sodium PHENYLBUTYRATE (PB) are aromatic fatty acids that can effect differentiation in a variety of cell lines at doses that may be clinically attainable
——————————————————————
Pg. 1760
——————————————————————
PB has been successfully administered to patients with urea acid cycle disorders and sickle cell anemia for extended periods of time, and NO HEMATOLOGICAL TOXICITY has been reported
——————————————————————
Significant HEMATOLOGICAL TOXICITY was not reported in a Phase I trial of PA in patients with malignancy
——————————————————————
Pg. 1761
——————————————————————
Because of its ATTRACTIVE CLINICAL TOXICITY PROFILE, PB represents an excellent candidate for clinical trials in this group of disorders
======================================
[21] 11.–.12/1997 Antineoplaston AS2-1 exhibits cytostatic growth inhibition of human hepatocellular carcinoma cells in vitro and SHOWED MINIMUM ADVERSE EFFECTS in phase I clinical trial
======================================
[22] 6/1999 Burkitt’s lymphoma (BL) is readily treated malignancy, recurrences, as well as disease arising in immunosuppressed patients, are notoriously resistant to conventional therapeutic approaches
——————————————————————
Using in vitro models of EBV-transformed lymphoblastoid as well as BL cell lines, we demonstrate increased expression of genes coding for HLA class I and EBV latent proteins by differentiation inducer PHENYLBUTYRATE (PB)
——————————————————————
Aromatic fatty acid also caused cytostasis associated with sustained declines in c-myc expression, a direct antitumor effect that was independent of EBV status
——————————————————————
Findings may have clinical relevance because in vitro activity has been observed with PB concentrations that are
WELL TOLERATED and nonimmunosuppressive in humans, a desirable feature for different patient populations afflicted with this disease
======================================
[23] 8/2001 PHENYLBUTYRATE (PB) is aromatic fatty acid with multiple mechanisms of action including histone deacetylase inhibition
——————————————————————
Overall DRUG WELL TOLERATED with most common TOXICITIES being grade 1-2 DYSPEPSIA and FATIGUE
——————————————————————
Nonoverlapping dose-limiting TOXICITIES of NAUSEA/VOMITING and HYPOCALCEMIA were seen at 36 g/day
——————————————————————
PB (p.o.) IS WELL TOLERATED and achieves concentration in vivo shown to have biological activity in vitro
======================================
[24] 10/2001 Sodium PHENYLBUTYRATE (PB) demonstrates potent differentiating capacity in multiple hematopoietic and solid tumor cell lines
——————————————————————
Pharmacokinetics performed during and after first infusion period using validated high-performance liquid chromatographic assay and single compartmental pharmacokinetic model for PB and principal metabolite, PHENYLACETATE
——————————————————————
24 patients with hormone refractory prostate cancer being predominant tumor type
——————————————————————
All evaluable for TOXICITY and response
——————————————————————
Dose escalated 150 to 515 mg/kg/day
——————————————————————
One patient at 515 mg/kg/day and one at 345 mg/kg/day experienced this DLT
——————————————————————
Maximum tolerated dose 410 mg/kg/day for 5 days
——————————————————————
Recommended Phase II dose 410 mg/kg/day for 120 h
——————————————————————
Dose-limiting TOXICITY (DLT) was neuro-cortical, exemplified by EXCESSIVE SOMNOLENCE and CONFUSION and accompanied by clinically significant HYPOKALEMIA, HYPONATREMIA, and HYPERURICEMIA
——————————————————————
Other TOXICITIES mild, including FATIGUE and NAUSEA
——————————————————————
DLT in Phase I study for infusional PB
given for 5 days every 21 days is neuro-cortical in nature
——————————————————————
TOXICITY resolved < or =12 h of discontinuing infusion
======================================
[25] 2003 Case of survival for nearly 8 years after treatment of unresectable multiple liver metastases from colon cancer, using microwave ablation and NONTOXIC ANTITUMOR AGENT, ANTINEOPLASTONS
——————————————————————
72-year-old man diagnosed with adenocarcinoma of ascending colon and 14 bilateral liver metastases underwent right hemicolectomy combined with microwave ablation of 6 metastatic liver tumors
——————————————————————
Antineoplaston A10 given intravenously, followed by oral antineoplaston AS2-1
——————————————————————
Patient underwent 2nd and 3rd microwave ablation of recurrent tumors, and has survived for nearly 8 years WITHOUT SUFFERING ANY SERIOUS ADVERSE EFFECTS
——————————————————————
Currently FREE FROM CANCER
——————————————————————
Demonstrates potential effectiveness of NONTOXIC ANTITUMOR AGENT, ANTINEOPLASTONS, for controlling liver metastases from colon cancer
======================================
[26] 4/2005 Determined maximum tolerated dose (MTD), TOXICITY profile of … oral sodium PHENYLBUTYRATE (PB) in patients with recurrent malignant gliomas
——————————————————————
All PB doses of 9, 18, and 27 g/day WELL TOLERATED
——————————————————————
At 36 g/day, 2 of 4 patients developed dose-limiting grade 3 FATIGUE and SOMNOLENCE
——————————————————————
At MTD of 27 g/day, one of 7 patients developed reversible grade 3 SOMNOLENCE
======================================
[27] 4/2007 PHENYLBUTYRATE (PBA), and its metabolite PHENYLACETATE (PAA), induce growth inhibition and cellular differentiation in multiple tumor models
——————————————————————
Conversion of PBA to PAA and PHENYLACETYLGLUTAMINE (PAG) documented without catabolic saturation
——————————————————————
THERAPY WELL TOLERATED OVERALL
——————————————————————
Common ADVERSE EFFECTS included grade 1 NAUSEA/VOMITING, FATIGUE, and LIGHTHEADEDNESS
——————————————————————
Dose limiting TOXICITIES were SHORT-TERM MEMORY LOSS, SEDATION, CONFUSION, NAUSEA, and VOMITING
——————————————————————
Administration of PBA twice-daily infusion schedule is SAFE
======================================
None of the above publications indicate that antineoplastons are toxic as Gorski would have people believe

12/12/2011 Gorski published his attempt at trying to explain why antineoplastons are supposedly toxic
======================================
What Dr. Stanislaw Burzynski doesn’t want you to know about antineoplastons
——————————————————————
http://scienceblogs.com/insolence/2011/12/12/what-dr-stanislaw-burzynski-doesnt-want/
======================================
Gorski posited:

“He’s also prescribing huge doses of antineoplastons (up to 25 g/kg/d for A10 and 80 mg/kg/d for AS-2.1, as we have seen). both of these are so far above the maximal tolerated dose of 300 mg/kg/d determined in the phase I trial I cited above as to be terrifying”

In support of his “theory”, Gorski provided a link to the National Cancer Institute (NCI) at the National Institutes of Health (NIH):
——————————————————————
http://www.cancer.gov/cancertopics/pdq/cam/antineoplastons/healthprofessional/Table1
——————————————————————
However, as is the case with a lot of Gorski’s lame research, he makes you search for what he is referring to:

[14]Ba Primitive neuroectodermal tumor (13)

A10/AS2-1

Max dose: A10: 25 g/kg/d; AS2-1: 0.6 g/kg/d

Does this support Gorski’s “toxic theory”?
======================================
[28] 2005
——————————————————————
5 years 7 months (1-11) median age
——————————————————————
13 / 100% – children with recurrent disease or high risk
——————————————————————
5 / 38% – weren’t treated earlier with radiation therapy or chemotherapy
——————————————————————
3 / 23% – Complete Response
1 / 8% – Partial Response
4 / 31% – Stable Disease
5 / 38% – Progressive Disease
——————————————————————
6 / 46% – Survived 5+ years from initiation of ANP
——————————————————————
Serious side effects:
1 – anemia
1 – fever
1 – granulocytopenia
——————————————————————
average dosage of A10 was 10.3 g/kg/d and of AS2-1 was 0.38 g/kg/d
——————————————————————
REDUCED TOXICITY MAKES ANP PROMISING for very young children, patients at high risk of complication of standard therapy, and patients with recurrent tumors
======================================
The above sure does NOT support Gorski’s “toxic theory”

When science based medicine keeps saying the following:
======================================
[9] 9/1994 increasing incidence of melanoma and POOR RESPONSIVENESS OF DISSEMINATED DISEASE TO CONVENTIONAL TREATMENT CALL FOR DEVELOPMENT OF NEW THERAPEUTIC APPROACHES
======================================
[29] 9/27/1995 (7/17/2006) Alterations in expression of ras oncogenes are characteristic of wide variety of human neoplasms
——————————————————————
Accumulating evidence has linked elevated ras expression with disease progression and FAILURE OF TUMORS TO RESPOND TO CONVENTIONAL THERAPIES, INCLUDING RADIOTHERAPY AND CERTAIN CHEMOTHERAPIES
——————————————————————
observations led us to investigate response of ras-transformed cells to differentiation-inducer PHENYLACETATE (PA)
——————————————————————
Interestingly, IN CONTRAST TO THEIR RELATIVE RESISTANCE TO RADIATION and doxorubicin, ras-transformed cells were significantly more sensitive to PA than their parental cells
======================================
[30] 5/1996 CYOTOXIC CHEMOTHERAPIES OFTEN GIVE RISE TO MULTIDRUG RESISTANCE, WHICH REMAINS MAJOR PROBLEM IN CANCER MANAGEMENT
————————————————————
IN PURSUIT OF ALTERNATIVE TREATMENTS FOR CHEMORESISTANT TUMOR CELLS, we tested response of multidrug-resistant (MDR) tumor cell lines to aromatic fatty acids PHENYLACETATE (PA) and PHENYLBUTYRATE (PB), 2 differentiation inducers currently in clinical trials
======================================
[15] 1996 Antineoplastons, first described by Burzynski, are naturally occurring peptides and amino acid derivatives which control neoplastic growth
——————————————————————
reported cytostatic inhibitory effect of A10 on human hepatocellular carcinoma cells and differentiation inducing effect of AS2-1 on various tumor cells suggest potential benefit for treatment of human hepatocellular carcinoma since TUMOR RECURS FREQUENTLY DESPITE INITIAL SUCCESSFUL TREATMENT
======================================
[31] 7/1997 Children with malignant GLIOMAS THAT PROGRESSED AFTER CONVENTIONAL THERAPY
——————————————————————
0 / 0% – EXHIBITED CLEAR-CUT TUMOR regression
======================================
[32] 2000 treatment combination PRODUCED NO SIGNIFICANT CHANGE in overall POOR prognosis of patients
——————————————————————
Most tumors responded initially to treatment but RECCURED as study progressed
——————————————————————
Based on POOR RESULTS, recommend ALTERNATIVE TREATMENTS be tested in patients with this type of tumor
======================================
[33] At time of approval, NO RESULTS were available from randomized controlled trials in refractory ANAPLASTIC ASTROCYTOMA that show clinical benefit such as improvement in disease-related symptoms or prolonged survival
======================================
[34] 12/2000 NO CLEAR PROOF OF EFFICACY
——————————————————————
NO BETTER THAN SURVIVAL BEFORE THE INTRODUCTION OF temozolomide
======================================
[35] 2002 p53 tumor suppressor gene plays important role in protecting cells from developing undesirable proliferation
——————————————————————
Mutant p53 gene or malfunctioning p53 protein found in more than 50% of cancer cells impedes DNA repair or apoptosis induction
——————————————————————
MAY BE WHY SOME CANCERS GAIN RESISTANCE TO CHEMOTHERAPY AND RADIATION AND BECOME MORE RESISTANT AFTER FREQUENT CANCER TREATMENTS
======================================
[36] 2004 outcome for patients with either type of tumor is POOR when STANDARD multimodality THERAPY IS USED
——————————————————————
children are ideal candidates for INNOVATIVE TREATMENT approaches
——————————————————————
33 / 100% – DIED OF DISEASE PROGRESSION
——————————————————————
administration of temozolomide after RT DIDN’T ALTER POOR PROGNOSIS associated with newly diagnosed diffuse BRAINSTEM GLIOMA in children
======================================
[37] 2/2008 addition of vincristine and oral VP-16 to standard external beam radiation causes moderate toxicity and DOESN’T IMPROVE SURVIVAL OF CHILDREN WITH DIFFUSE INTRINSIC BRAIN STEM GLIOMA
======================================
[38] 5/6/2009 Currently, NO DATA available from randomized controlled trials demonstrating improvement in disease-related symptoms or increased survival with Avastin in GLIOBLASTOMA
======================================
[39] 10/12/2011 Afinitor (ubependymal giant cell ASTROCYTOMA (SEGA) brain tumor)
——————————————————————
none of their tumors went away completely
======================================
[18] 8/1997 aromatic fatty acids PHENYLACETATE (PA) and PHENYLBUTYRATE (PB) are novel antitumor agents currently under clinical evaluation
————————————————————
ability to induce tumor differentiation in laboratory models and LOW CLINICALTOXICITY PROFILE makes them promising candidates for COMBINATION WITH CONVENTIONAL THERAPIES
======================================
So what does Gorski think is going to fill the void?

His clinical trial drug ?

The potentially profitable drug Gorski is in the process of conducting a clinical trial for is the ALS drug Riluzole, made by Sanofi-Aventis and marketed as Rilutek

Apparently, David Gorski has had his eye on that drug for a long time, but as a possible treatment for breast cancer

As suggested by a 2008-2009 webpage of a breast cancer website:

“Three years ago in another cancer (melanoma), Dr. Gorski’s collaborators found that glutamate might have a role in promoting the transformation of the pigmented cells in the skin (melanocytes) into the deadly skin cancer melanoma”

“More importantly for therapy, it was found that this protein can be blocked with drugs, and, specifically, in melanoma cell lines and tumor models of melanoma using a drug originally designed to treat ALS and already FDA-approved for that indication (Riluzole) can inhibit the growth of melanoma.”
————————————————————
http://www.ageofautism.com/2010/06/david-gorskis-financial-pharma-ties-what-he-didnt-tell-you.html
————————————————————
Better luck next time with your personal MUD-targeted Skeptic therapy Gorski

� � � � � � � � � � � � � � � � �
References:
————————————————————
Dvorit D. Samid learned about antineoplastons from Burzynski
� � � � � � � � � � � � � � � � �
[1] 4/1/1992
� � � � � � � � � � � � � � � � �
SAMID, D., Shack, S., and Sherman, l.. T.
http://www.ncbi.nlm.nih.gov/pubmed/1372534/
Cancer Res., 52: 1988-1992, 1992
http://www.ncbi.nlm.nih.gov/m/pubmed/1372534/
Cancer Res 1992;52:1988-1992
http://m.cancerres.aacrjournals.org/content/52/7/1988.abstract
Cancer Res April 1, 1992 52; 1988v I
http://cancerres.aacrjournals.org/content/52/7/1988
Cancer Res. 1992 Apr 1;52(7):1988-92
http://m.cancerres.aacrjournals.org/content/52/7/1988.full.pdf
Cancer Res 52:1988,1992
http://m.cancerres.aacrjournals.org/content/52/7/1988.full.pdf#page=1
SAMID D, Shack S, Ti-Sherman L
Clinical Pharmacology Branch, National Cancer Institute, Bethesda, Maryland
PHENYLACETATE-A novel nontoxic inducer of TUMOR CELL differentiation
↵1 Supported by Elan Pharmaceutical Corporation Grant G174ED
Reference: 12 (SAMID, D.)
� � � � � � � � � � � � � � � � �
[2] .8/20/1992
� � � � � � � � � � � � � � � � �
Dover GJ, Brusilow S, SAMID D. Increased fetal hemoglobin in patients receiving sodium 4-PHENYLBUTYRATE. N Engl J Med. 1992 Aug 20;327(8):569–570
http://www.ncbi.nlm.nih.gov/pubmed/1378939/
N Engl J Med. 1992 Aug 20;327(8):569-70
http://www.ncbi.nlm.nih.gov/m/pubmed/1378939/
August 20, 1992
N Engl J Med 1992; 327:569-570
http://www.nejm.org/doi/full/10.1056/NEJM199208203270818
N Engl J Med 327569, 1992
Dvorit Samid, Ph.D
National Cancer Institute, Bethesda, MD
� � � � � � � � � � � � � � � � �
[3] 9/15/1992
� � � � � � � � � � � � � � � � �
SAMID D, Yeh A, Prasanna P. Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood. 1992 Sep 15;80(6):1576–1581
http://www.ncbi.nlm.nih.gov/pubmed/1381630/
Blood. 1992 Sep 15;80(6):1576-81
http://www.ncbi.nlm.nih.gov/m/pubmed/1381630/
Blood September 15, 1992 vol. 80 no. 6 1576-1581
http://m.bloodjournal.hematologylibrary.org/content/80/6/1576.full.pd
Blood 80:1576, 1992
http://m.bloodjournal.hematologylibrary.org/content/80/6/1576.abstract
Blood 80(6):1576–1581
http://m.bloodjournal.hematologylibrary.org/content/80/6/1576.full.pdf
Clinical Pharmacology Branch, National Cancer Institute, Bethesda, MD
SAMID D References: 15, 20-21 and 34
� � � � � � � � � � � � � � � � �
[4] 5/1993
� � � � � � � � � � � � � � � � �
SAMID D, Shack S , Myers CE . Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by NONTOXIC pharmacological concentrations of PHENYLACETATE . J. Clin. Invest . 1993;91:2288
http://www.ncbi.nlm.nih.gov/pubmed/8486788/
J Clin Invest. 1993 May;91(5):2288-95
http://www.ncbi.nlm.nih.gov/m/pubmed/8486788/
J Clin Invest. 1993 May; 91(5): 2288–2295
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC288233/
Published in Volume 91, Issue 5 (May 1993)
http://m.jci.org/articles/view/116457
J Clin Invest. 1993;91(5):2288–2295
1993, The American Society for Clinical Investigation
http://m.jci.org/articles/view/116457/pdf.mobile
J Clin Invest 91:2288, 1993
PMCID: PMC288233
doi:10.1172/JCI116457
Clinical Pharmacology Branch, National Cancer Institute, Bethesda, Maryland
SAMID D References: 9, 13-14, 17 and 33
� � � � � � � � � � � � � � � � �
[5] .10/1/1993
� � � � � � � � � � � � � � � � �
Enhanced fetal
hemoglobin production by PHENYLACETATE and 4-PHENYLBUTYRATE in erythroid precursors derived from normal blood donors and patients with sickle cell anemia and P-thalassemia
http://www.ncbi.nlm.nih.gov/pubmed/7691251/
Blood. 1993 Oct 1;82(7):2203-9
http://www.ncbi.nlm.nih.gov/m/pubmed/7691251/
Blood 822203, 1993
http://m.bloodjournal.hematologylibrary.org/content/82/7/2203.full.pd
Blood October 1, 1993 vol. 82 no. 7 2203-2209
http://m.bloodjournal.hematologylibrary.org/content/82/7/2203.abstract
1993 82: 2203-2209
http://m.bloodjournal.hematologylibrary.org/content/82/7/2203.full.pdf
Blood 82(7):2203–2209
Department of Hematology, Hadassah University Hospital, Jerusalem, Israel
Fibach E, Prasanna P, Rodgers GP, SAMID D
SAMID D References: 15, 19-21 and 32
� � � � � � � � � � � � � � � � �
[6] 2/15/1994
� � � � � � � � � � � � � � � � �
SAMID, D., Ram, Z., Hudgins, W. R., Shack, S., Liu, L., Waibridge, S., Oldfield, E. H., and Myers, C. E. Selective activity of PHENYLACETATE against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res., 54: 891-895, 1993
http://www.ncbi.nlm.nih.gov/pubmed/8313377/
Cancer Res. 1994 Feb 15;54(4):891-5
http://www.ncbi.nlm.nih.gov/m/pubmed/8313377/
Cancer Res February 15, 1994 54; 891
http://cancerres.aacrjournals.org/content/54/4/891/
Cancer Res 1994;54:891-895
Clinical Pharmacology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
Work supported by funds from Elan Pharmaceutical Research Corporation through Cooperative Research and Development Agreement (CACR-0139)
� � � � � � � � � � � � � � � � �
[7] 4/1/1994
� � � � � � � � � � � � � � � � �
A phase I and pharmacokinetic study of intravenous PHENYLACETATE in patients with cancer
http://www.ncbi.nlm.nih.gov/pubmed/8137283
Cancer Res. 1994 Apr 1;54(7):1690-4
http://www.ncbi.nlm.nih.gov/m/pubmed/8137283
Cancer Res 54(7):1690-4 (1994), PMID.8137283
http://m.cancerres.aacrjournals.org/content/54/7/1690.abstract
Clinical Pharmacology Branch, National Cancer Institute, NIH, Bethesda, Maryland
http://m.cancerres.aacrjournals.org/content/54/7/1690.full.pdf
Thibault A, Cooper MR, Figg WD, Venzon DJ, Sartor AO, Tompkins AC, Weinberger MS, Headlee DJ, McCall NA, SAMID D, et al.
http://cancerres.aacrjournals.org/content/54/7/1690
Study supported in part by grant from Elan Pharmaceutical Research Co
SAMID D
References: 8-12
BURZYNSKI
Reference: 13
13. BURZYNSKI, S. R., Kubove E., Burzynski, B. Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1. Drugs Exp. Clin. Res., 16: 361-369, 1990
http://www.ncbi.nlm.nih.gov/pubmed/2152694/
Drugs Exp Clin Res. 1990;16(7):361-9
http://www.ncbi.nlm.nih.gov/m/pubmed/2152694/
� � � � � � � � � � � � � � � � �
[8] 6/1/1994
� � � � � � � � � � � � � � � � �
Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with PHENYLACETATE.
http://www.ncbi.nlm.nih.gov/pubmed/8187079/
Cancer Res 54:2934-2927, 1994
http://www.ncbi.nlm.nih.gov/m/pubmed/8187079/
Cancer Res. 1994 Jun 1;54(11):2923-7
http://m.cancerres.aacrjournals.org/content/54/11/2934.abstract?ijkey=03bc67e581ef77536842806b949046916458d548&keytype2=tf_ipsecsha
Cancer Res 54(11):2923–2927
http://m.cancerres.aacrjournals.org/content/54/11/2923.abstract
Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland
http://m.cancerres.aacrjournals.org/content/54/11/2923.full.pdf
Ram Z, SAMID D, Walbridge S, et al:
http://cancerres.aacrjournals.org/content/54/11/2923
� � � � � � � � � � � � � � � � �
[9] 1994
� � � � � � � � � � � � � � � � �
Liu L , Shack S , Stetler-Stevenson WG , Hudgins WR , SAMID D . Differentiation of cultured human melanoma cells induced by the aromatic fatty acids PHENYLACETATE and PHENYLBUTYRATE . J. Invest. Dermatol . 1994;103:335
http://www.ncbi.nlm.nih.gov/pubmed/8077698/
J Invest Dermatol. 1994 Sep;103(3):335-40
http://www.ncbi.nlm.nih.gov/m/pubmed/8077698/
Clinical Pharmacology Branch, National Cancer Institute, Bethesda, Maryland
� � � � � � � � � � � � � � � � �
[10] 4/1995
� � � � � � � � � � � � � � � � �
Disposition of PHENYLBUTYRATE and its metabolites, PHENYLACETATE and PHENYLACETYLGLUTAMINE.
J Clin Pharmacol 35:368-373, 1995 Abstract
http://www.ncbi.nlm.nih.gov/pubmed/7650225/
J Clin Pharmacol 35:368-373, 1995 Abstract
http://www.ncbi.nlm.nih.gov/m/pubmed/7650225/
The Journal of Clinical Pharmacology
Volume 35, Issue 4, pages 368–373, April 1995
http://m.jcp.sagepub.com/content/35/4/368.abstract?ijkey=74bff0d86ce76b404728762fe2a1bfde1641fa41&keytype2=tf_ipsecsha
J Clin Pharmacol. 1995 Apr;35(4):368-73
http://onlinelibrary.wiley.com/doi/10.1002/j.1552-4604.1995.tb04075.x/abstract;jsessionid=DFDEF1599D764E2845EC2897269C198B.d01t01
Article first published online: 8 MAR 2013
http://onlinelibrary.wiley.com/doi/10.1002/j.1552-4604.1995.tb04075.x/abstract;jsessionid=43600D49608A093971D675F3DB5FF13D.d01t03
Piscitelli SC, Thibault A, Figg WD, et al: (SAMID D)
http://jcp.sagepub.com/content/35/4/368
Pharmacy Department, National Institutes of Health, Bethesda, Maryland, USA
DOI: 10.1002/j.1552-4604.1995.tb04075.x
http://m.jcp.sagepub.com/content/35/4/368.abstract?ijkey=74bff0d86ce76b404728762fe2a1bfde1641fa41&keytype2=tf_ipsecsha
� � � � � � � � � � � � � � � �
[11] 6/15/1995
� � � � � � � � � � � � � � � �
Phase I study of PHENYLACETATE administered twice daily to patients with cancer
http://www.ncbi.nlm.nih.gov/pubmed/7773944/
Cancer. 1995 Jun 15;75(12):2932-8
http://www.ncbi.nlm.nih.gov/m/pubmed/7773944/
Cancer 75(12):2932–2938
Clinical Pharmacology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Thibault A, SAMID D, Cooper MR, Figg WD, Tompkins AC, Patronas N, et al
� � � � � � � � � � � � � � � � �
[12] 10/12/1995
� � � � � � � � � � � � � � � � �
Cytostatic activity of PHENYLACETATE and derivatives against tumor cells:
Correlation with lipophilicity and inhibition of protein prenylation.
http://www.ncbi.nlm.nih.gov/pubmed/7488244/
Biochem Pharmacol. 1995 Oct 12;50(8):1273-9
http://www.ncbi.nlm.nih.gov/m/pubmed/7488244/
Biochem Pharmacol 50:1273-1279, 1995
http://www.sciencedirect.com/science/article/pii/0006295295020133
Clinical Pharmacology Branch, National Cancer Institute, Bethesda, MD, USA
� � � � � � � � � � � � � � � � �
[13] 10/1995
� � � � � � � � � � � � � � � � �
Stockhammer G, Manley GT, Johnson R, et al: (SAMID D) Inhibition of proliferation and induction of differentiation in medulloblastoma and astrocytoma-derived cell lines with PHENYLACETATE. J Neurosurg 83:672-681, 1995
http://www.ncbi.nlm.nih.gov/pubmed/7674018/
J Neurosurg. 1995 Oct;83(4):672-81
http://www.ncbi.nlm.nih.gov/m/pubmed/7674018/
Cotzias Laboratory of Neuro-Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
http://thejns.org/doi/abs/10.3171/jns.1995.83.4.0672?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed&amp;
� � � � � � � � � � � � � � � � �
[14] 1995
� � � � � � � � � � � � � � � � �
Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients
http://www.ncbi.nlm.nih.gov/pubmed/8667595
Kurume Med J. 1995;42(4):241-9
http://www.ncbi.nlm.nih.gov/m/pubmed/8667595
The Kurume Medical Journal
Vol. 42 (1995) No. 4 P 241-249
https://www.jstage.jst.go.jp/article/kurumemedj1954/42/4/42_4_241/_article
JST.Journalarchive/kurumemedj1954/42.241
https://www.jstage.jst.go.jp/article/kurumemedj1954/42/4/42_4_241/_pdf
Department of Anesthesiology, Kurume University School of Medicine, Japan
http://dx.doi.org/10.2739/kurumemedj.42.241
Tsuda H, Hara H, Eriguchi N, Nishida H, Yoshida H, Kumabe T, Sugita Y
https://www.jstage.jst.go.jp/article/kurumemedj1954/42/4/42_4_241/_article/references
Burzynski References: 1 – 3 and 5
Nishida et al. (Japan) A-10 Reference: 4 and 7
Muldoon et al. A-10 Reference: 6
� � � � � � � � � � � � � � � � �
[15] 1996
� � � � � � � � � � � � � � � � �
Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma
Tsuda H (Japan)
http://www.ncbi.nlm.nih.gov/pubmed/8755117
Kurume Med J. 1996;43(2):137-47
http://www.ncbi.nlm.nih.gov/m/pubmed/8755117
Department of Anesthesiology, Kurume University School of Medicine, Japan
http://www.jstage.jst.go.jp/article/kurumemedj1954/43/2/43_2_137/_article
Burzynski References: 1 – 3, 5 and 7
http://www.jstage.jst.go.jp/article/kurumemedj1954/43/2/43_2_137/_article/references
SAMID Reference: 13 (who learned from Burzynski re PHENYLACETATE)
http://www.jstage.jst.go.jp/article/kurumemedj1954/43/2/43_2_137/_pdf
Nishida et al. (Japan) A10 Reference: 4 and 10
Muldoon et al. A10 Reference: 8
� � � � � � � � � � � � � � � �
[16] 5/1996
� � � � � � � � � � � � � � � �
Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and PHENYLBUTYRATE
http://www.ncbi.nlm.nih.gov/pubmed/9816242/
Clin Cancer Res. 1996 May;2(5):865-72
http://www.ncbi.nlm.nih.gov/m/pubmed/9816242/
Clin Cancer Res 2(5):865–872
http://m.clincancerres.aacrjournals.org/content/2/5/865.abstract
Clinical Pharmacology Branch, National Cancer Institute, Bethesda, Maryland, USA
http://m.clincancerres.aacrjournals.org/content/2/5/865.full.pdf
Shack S, Miller A, Liu L, Prasanna P, Thibault A, SAMID D
http://clincancerres.aacrjournals.org/content/2/5/865
� � � � � � � � � � � � � � � � �
[17] 12/1996
� � � � � � � � � � � � � � � � �
Gorospe M, Shack S, Guyton KZ, et al: (SAMID D)
Up-regulation and functional role of p21Waf1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by PHENYLACETATE. Cell Growth Differ 7:1609-1615, 1996
http://www.ncbi.nlm.nih.gov/pubmed/8959328/
Cell Growth Differ. 1996 Dec;7(12):1609-15
http://www.ncbi.nlm.nih.gov/m/pubmed/8959328/
Cell Growth Differ 7(12):1609–1615
http://cgd.aacrjournals.org/cgi/reprint/7/12/1609.pdf
Laboratory of Cellular and Molecular Biology, Gerontology Research Center, National Institute on Aging, NIH, Baltimore, Maryland, USA
� � � � � � � � � � � � � � � � �
[18] 8/1997
� � � � � � � � � � � � � � � � �
Miller AC, Whittaker T, Thibault A, et al: (SAMID D)
Modulation of radiation response of human tumor cells by the differentiation inducers, PHENYLACETATE and PHENYLBUTYRATE. Int J Radiat Biol 72:211-218, 1997
http://www.ncbi.nlm.nih.gov/pubmed/9269314/
Int J Radiat Biol. 1997 Aug;72(2):211-8
http://www.ncbi.nlm.nih.gov/m/pubmed/9269314/
Armed Forces Radiobiology, Research Institute, Bethesda, MD, USA
� � � � � � � � � � � � � � � � �
[19] 1997
� � � � � � � � � � � � � � � � �
PHENYLACETATE and PHENYLBUTYRATE as novel, NONTOXIC differentiation inducers
http://www.ncbi.nlm.nih.gov/pubmed/9547596
Adv Exp Med Biol (1997), PMID.9547596
http://www.ncbi.nlm.nih.gov/m/pubmed/9547596
Adv Exp Med Biol. 1997;400A:501-5
http://link.springer.com/chapter/10.1007%2F978-1-4615-5325-0_67
DOI
10.1007/978-1-4615-5325-0_67
http://link.springer.com/content/pdf/10.1007%2F978-1-4615-5325-0_67.pdf
Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury 2
Advances in Experimental Medicine and Biology Volume 400, 1997, pp 501-505
Clinical Pharmacology Branch, National Cancer Institute, Bethesda, MD USA
D D SAMID, W R WR Hudgins, … C E CE Myers
� � � � � � � � � � � � � � � �
[20] 10/1997
� � � � � � � � � � � � � � � �
Impact of the putative differentiating agents sodium PHENYLBUTYRATE and sodium PHENYLACETATE on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells
http://www.ncbi.nlm.nih.gov/pubmed/9815560/
Clin Cancer Res. 1997 Oct;3(10):1755-62
http://www.ncbi.nlm.nih.gov/m/pubmed/9815560/
Clin Cancer Res October 1997 3; 1755
http://m.clincancerres.aacrjournals.org/content/3/10/1755.full.pd
Clin Cancer Res. 1997a;3:1755–1762
http://m.clincancerres.aacrjournals.org/content/3/10/1755.abstract
The Johns Hopkins Oncology Center, Baltimore, Maryland, USA
http://m.clincancerres.aacrjournals.org/content/3/10/1755.full.pdf
Gore SD, SAMID D, Weng LJ
� � � � � � � � � � � � � � � � �
[21] 11.–.12/1997
� � � � � � � � � � � � � � � � �
Antineoplaston AS2-1 for maintenance therapy in liver cancer
H Tsuda phase I clinical trial
http://www.ncbi.nlm.nih.gov/pubmed/21590224
Oncol Rep. 1997; 4:1213- 1216
http://www.ncbi.nlm.nih.gov/m/pubmed/21590224
Oncol Rep. 1997 Nov-Dec;4(6):1213-6
http://www.spandidos-publications.com/or/4/6/1213
Oncol Rep 4 (6):1213-6 (1997)
Oncology Reports
4 (6):1213-6
KURUME UNIV,SCH MED,DEPT SURG,KURUME,FUKUOKA,JAPAN. KURUME UNIV,SCH MED,DEPT INTERNAL MED,KURUME,FUKUOKA,JAPAN. KURUME UNIV,SCH MED,DEPT RADIOL,KURUME,FUKUOKA,JAPAN
� � � � � � � � � � � � � � � �
[22] 6/1999
� � � � � � � � � � � � � � � �
PHENYLBUTYRATE induces cell differentiation and modulates Epstein-Barr virus gene expression in Burkitt’s lymphoma cells
http://www.ncbi.nlm.nih.gov/pubmed/10389940/
Clin Cancer Res. 1999 Jun;5(6):1509-16
http://www.ncbi.nlm.nih.gov/m/pubmed/10389940/
Clin Cancer Res 5(6):1509–1516
http://m.clincancerres.aacrjournals.org/content/5/6/1509.abstract
Clin Cancer Res June 1999 5; 1509
http://m.clincancerres.aacrjournals.org/content/5/6/1509.long
Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
http://clincancerres.aacrjournals.org/content/5/6/1509
Bar-Ner M, Thibault A, Tsokos M, Magrath IT, SAMID D
Supported in part by funds from Elan Pharmaceutical Research Corporation
� � � � � � � � � � � � � � � � �
[23] 8/2001
� � � � � � � � � � � � � � � � �
A phase Idose escalation and bioavailability study of oral sodium PHENYLBUTYRATE in patients with refractory solid tumor malignancies
http://www.ncbi.nlm.nih.gov/pubmed/11489804
Clin Cancer Res. 2001 Aug;7(8):2292-.300
http://www.ncbi.nlm.nih.gov/m/pubmed/11489804
Clin Cancer Res 7(8):2292-.300 (2001), PMID.11489804
http://m.clincancerres.aacrjournals.org/content/7/8/2292.long
Division of Medical Oncology, Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, USA
J Gilbert, S D Baker, … M A Carducci
SAMID D References: 2-3, 5-6, 15 and 20
� � � � � � � � � � � � � � � � �
[24] 10/2001
� � � � � � � � � � � � � � � � �
A Phase I clinical and pharmacological evaluation of sodium PHENYLBUTYRATE on an 120-h infusion schedule
http://www.ncbi.nlm.nih.gov/pubmed/11595694
Clin Cancer Res. 2001 Oct;7(10):3047-55
http://www.ncbi.nlm.nih.gov/m/pubmed/11595694
Clin Cancer Res 7(10):3047-55 (2001), PMID.11595694
http://m.clincancerres.aacrjournals.org/content/7/10/3047.long
Division of Medical Oncology, The Johns Hopkins Oncology Center, Bunting-Blaustein Cancer Research Building, Baltimore, MD, USA
M A Carducci, J Gilbert, … R C Donehower
SAMID D References: 10-11, 13-14, 17-18, 23-24, 27, 33, 40-41 and 47
� � � � � � � � � � � � � � � � �
[25] 2003
� � � � � � � � � � � � � � � � �
Long-term survival following treatment with antineoplastons for colon cancer with unresectable multiple liver metastases: report of a case
http://www.ncbi.nlm.nih.gov/pubmed/12768372
Long-Term Survival Following Treatment with Antineoplastonsfor Colon Cancer with Unresectable Multiple Liver Metastases:
Report of a Case
A10 and AS2-1 – Phase II Clinical Trial
Hideaki Tsuda
http://www.springerlink.com/content/b48ch3ha165nbrqp
Surg Today. 2003;33(6):448-53
http://link.springer.com/article/10.1007%2Fs10595-002-2503-2
Surg Today 2003; 33:448–53
http://link.springer.com/content/pdf/10.1007%2Fs10595-002-2503-2
Surg Today. 2003; 33:448-453
http://link.springer.com/article/10.1007%2Fs10595-002-2503-2?LI=true
33 (6):448-53
http://link.springer.com/content/pdf/10.1007%2Fs10595-002-2503-2
Surgery Today, Springer
http://sciencelinks.jp/j-east/article/200313/000020031303A0389449.php
Surg Today 2003
http://sciencelinks.jp/j-east/article/200313/000020031303A0389449.php
DOI: 10.1007/s10595-002-2503-2
http://ci.nii.ac.jp/naid/10015483373
Department of Surgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan
http://ci.nii.ac.jp/naid/10015483373
� � � � � � � � � � � � � � � �
[26] 4/2005
� � � � � � � � � � � � � � � �
Oral sodium PHENYLBUTYRATE in patients with recurrent malignant gliomas:

A dose escalation and pharmacologic study
http://www.ncbi.nlm.nih.gov/pubmed/15831235/
Neuro Oncol. 2005 Apr;7(2):177-82
http://www.ncbi.nlm.nih.gov/m/pubmed/15831235/
Neuro-oncol. 2005 April; 7(2): 177–182 PMCID: PMC1871887
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1871887/pdf/neu0702p177.pdf
The New Approaches to Brain Tumor Therapy CNS Consortium, Winship Cancer Institute, Emory University, Atlanta, GA, USA
Buckner Reference: 3
SAMID D References: 12, 17 and 19-21
� � � � � � � � � � � � � � � � �
[27] 4/2007
� � � � � � � � � � � � � � � � �
Phase I dose escalation clinical trial of PHENYLBUTYRATE sodium administered twice daily to patients with advanced solid tumors
http://www.ncbi.nlm.nih.gov/pubmed/17053987
Invest New Drugs. 2007 Apr;25(2):131-8. Epub 2006 Oct 20
http://www.ncbi.nlm.nih.gov/m/pubmed/17053987
Investigational New Drugs
April 2007, Volume 25, Issue 2, pp 131-138
http://link.springer.com/article/10.1007%2Fs10637-006-9017-4
Invest New Drugs 25(2):131-8 (2007), PMID.17053987
Department of Medicine, Memorial Sloan-Kettering Cancer Center, Joan and Sanford I. Weill Medical College of Cornell Medical Center, New York, New York, USA
Luis H LH Camacho, Jon J Olson, … Mark G MG Malkin
SAMID D References: 4-5, 7, 20, 24, 30 and 32-38
� � � � � � � � � � � � � � � � �
[28] 2005
� � � � � � � � � � � � � � � � �
14. Burzynski SR, Weaver RA, Janicki T, et al.: Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1. Integr Cancer Ther 4 (2): 168-77, 2005
http://www.ncbi.nlm.nih.gov/pubmed/15911929/
Integr Cancer Ther. 2005 Jun;4(2):168-77
http://www.ncbi.nlm.nih.gov/m/pubmed/15911929/
� � � � � � � � � � � � � � � � �
[29] 9/27/1995
� � � � � � � � � � � � � � � � �
Increased susceptibility of ras-transformed cells to PHENYLACETATE is associated with inhibition of p21ras isoprenylation and phenotypic reversion. Int J Cancer 63:124-129, 1995
http://www.ncbi.nlm.nih.gov/pubmed/7558439/
Int J Cancer. 1995 Sep 27;63(1):124-9
http://www.ncbi.nlm.nih.gov/m/pubmed/7558439/
Clinical Pharmacology Branch, National Cancer Institute, Bethesda, MD, USA
http://onlinelibrary.wiley.com/doi/10.1002/ijc.2910630122/abstract
Int J Cancer 63:124-129, 1995
Int J Cancer. 1995 Sep 27;63(1):124-9.
http://onlinelibrary.wiley.com/doi/10.1002/ijc.2910630122/references
International Journal of Cancer
Volume 63, Issue 1, Article first published online: 17 JUL 2006
DOI: 10.1002/ijc.2910630122
Shack S, Chen L-C, Miller AC, et al: (SAMID D)
http://onlinelibrary.wiley.com/doi/10.1002/ijc.2910630122/abstract
Shack, S., Chen, L-C., Miller, A. C., Danesi, A., and SAMID, D. Int. J. Cancer, 63: 124-129, 1995
� � � � � � � � � � � � � � � � �
[30] 5/1996
� � � � � � � � � � � � � � � � �
Shack, S., Miller, A., Liu, L., Prasanna, P., Thibault, A., and SAMID, D.. Vulnerability of MULTIDRUG-RESISTANT TUMOR CELLS to the aromatic fatty acids PHENYLACETATE and PHENYLBUTYRATE. Clin. Cancer Res., 2: 865-872, 1996
http://www.ncbi.nlm.nih.gov/pubmed/9816242/
Clin Cancer Res. 1996 May;2(5):865-72
http://www.ncbi.nlm.nih.gov/m/pubmed/9816242/
Clinical Pharmacology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
http://m.clincancerres.aacrjournals.org/content/2/5/865.abstract

http://m.clincancerres.aacrjournals.org/content/2/5/865.full.pdf
� � � � � � � � � � � � � � � � �
[31] 7/1997
� � � � � � � � � � � � � � � � �
A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood
http://www.ncbi.nlm.nih.gov/pubmed/9815790/
Clin Cancer Res. 1997 Jul;3(7):1109-15
http://www.ncbi.nlm.nih.gov/m/pubmed/9815790/
Clin Cancer Res July 1997 3; 1109
http://m.clincancerres.aacrjournals.org/content/3/7/1109.full.pd
Department of Neurosurgery, Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA
http://clincancerres.aacrjournals.org/content/3/7/1109
� � � � � � � � � � � � � � � � �
[32] 2000
� � � � � � � � � � � � � � � � �
Radiation therapy and high-dose tamoxifen in the treatment of patients with diffuse BRAINSTEM GLIOMAS:

results of a Brazilian cooperative study
http://www.ncbi.nlm.nih.gov/pubmed/10715294/
Brainstem Glioma Cooperative Group
http://www.ncbi.nlm.nih.gov/m/pubmed/10715294/
J Clin Oncol 18, 1246-1253
http://m.jco.ascopubs.org/content/18/6/1246.long
� � � � � � � � � � � � � � � � �
[33]
� � � � � � � � � � � � � � � � �
http://clincancerres.aacrjournals.org/content/11/19/6767.full
� � � � � � � � � � � � � � � � �
[34] 12/2000
� � � � � � � � � � � � � � � � �
Temozolomide and ANAPLASTIC ASTROCYTOMA:

new indication
http://www.ncbi.nlm.nih.gov/pubmed/11475493/
Prescrire Int. 2000 Dec;9(50):170-1.
http://www.ncbi.nlm.nih.gov/m/pubmed/11475493/
� � � � � � � � � � � � � � � � �
[35] 2002
� � � � � � � � � � � � � � � � �
A novel strategy for remission induction and maintenance in cancer therapy
A10 and AS2-1
H Tsuda
http://www.ncbi.nlm.nih.gov/pubmed/11748457
Oncol Rep 2002;9:65–8
http://www.ncbi.nlm.nih.gov/m/pubmed/11748457
Oncol. Rep. 2002;9:65-68
http://www.spandidos-publications.com/or/9/1/65
Oncol Rep 9(1):65-8 (2002)
Oncology Reports, Spandidos Publications
Department of Anesthesiology, Kurume University, School of Medicine, Fukuoka-ken, Japan
� � � � � � � � � � � � � � � � �
[36] 2004
� � � � � � � � � � � � � � � � �
Supratentorial high-grade ASTROCYTOMA and DIFFUSE BRAINSTEM GLIOMA:

two challenges for the pediatric oncologist
http://www.ncbi.nlm.nih.gov/pubmed/15047924/
Oncologist. 2004;9(2):197-206.
http://www.ncbi.nlm.nih.gov/m/pubmed/15047924/
Oncologist 9, 197-206
http://m.theoncologist.alphamedpress.org/content/9/2/197.long
Division of Neuro-Oncology, Department of Hematology-Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
1/1/2005 (11/24/2004) – Role of temozolomide after radiotherapy for newly diagnosed diffuse BRAINSTEM GLIOMA in children:

results of a multiinstitutional study (SJHG-98)
http://www.ncbi.nlm.nih.gov/pubmed/15565574
Cancer. 2005 Jan 1;103(1):133-9.
http://www.ncbi.nlm.nih.gov/m/pubmed/15565574
Cancer 103, 133-139
http://onlinelibrary.wiley.com/doi/10.1002/cncr.20741/abstract;jsessionid=6717837591CCC8FCBD8E46163808E221.d03t01
Cancer
Volume 103, Issue 1, pages 133–139, 1 January 2005
http://onlinelibrary.wiley.com/doi/10.1002/cncr.20741/full
Article first published online: 24 NOV 2004
References:
http://onlinelibrary.wiley.com/doi/10.1002/cncr.20741/references
Cited By:
http://onlinelibrary.wiley.com/doi/10.1002/cncr.20741/citedby
DOI: 10.1002/cncr.20741
Department of Hematology-Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
——————————————————————
Cancer 103, 133-139
� � � � � � � � � � � � � � � � �
[37] 2/2008 (Article first published online: 2/2/2007)
� � � � � � � � � � � � � � � � �
Treatment of children with diffuse intrinsic BRAIN STEM GLIOMA with radiotherapy, vincristine and oral VP-16:

a Children’s Oncology Group phase II study
http://www.ncbi.nlm.nih.gov/pubmed/17278121
Pediatr Blood Cancer. 2008 Feb;50(2):227-30
http://www.ncbi.nlm.nih.gov/m/pubmed/17278121
University of Rochester Medical Center, Rochester, New York, USA
http://onlinelibrary.wiley.com/doi/10.1002/pbc.21154/abstract;jsessionid=DE7A67EFBAC1A184F6805F11CFC4F30B.d02t02
Article first published online: 2 FEB 2007
DOI: 10.1002/pbc.21154
� � � � � � � � � � � � � � � � �
[38] 5/6/2009
� � � � � � � � � � � � � � � � �
U.S. Food and Drug Administration (FDA) granted accelerated approval of Avastin (bevacizumab) for people with GLIOBLASTOMA (brain cancer) with progressive disease following prior therapy
——————————————————————
effectiveness of Avastin in AGGRESSIVE form of BRAIN CANCER based on improvement in objective response rate
——————————————————————
http://www.drugs.com/newdrugs/fda-grants-accelerated-approval-avastin-combination-paclitaxel-chemotherapy-first-line-advanced-852.html
According to FDA analysis of study
——————————————————————
Study AVF3708g
——————————————————————
Study NCI 06-C-0064E
——————————————————————
Efficacy of Avastin in GLIOBLASTOMA that progressed following prior therapy supported by another study that used same response assessment criteria as AVF3708g
——————————————————————
http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab
——————————————————————
http://www.drugs.com/newdrugs/fda-grants-accelerated-approval-avastin-brain-cancer-glioblastoma-has-progressed-following-prior-1342.html
� � � � � � � � � � � � � � � � �
[39] 10/12/2011 (Published online: 8/1/2011)
� � � � � � � � � � � � � � � � �
Everolimus tablets for patients with subependymal giant cell ASTROCYTOMA
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389821/
Expert Opin Pharmacother. Author manuscript; available in PMC 2012 July 5.
Published in final edited form as:
Expert Opin Pharmacother. 2011 October; 12(14): 2265–2269.
Published online 2011 August 1. doi: 10.1517/14656566.2011.601742
PMCID: PMC3389821
NIHMSID: NIHMS385824
——————————————————————
http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm231967.htm
� � � � � � � � � � � � � � � � �